Crystalline solid forms of BET inhibitors

JP7588622B2Active Publication Date: 2024-11-22INCYTE CORP
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022107131
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-09-21
Filing Date
2022-07-01
Publication Date
2024-11-22
Estimated Expiration
2037-06-19

Smart Images

  • Figure 0007588622000058
    Figure 0007588622000058
  • Figure 0007588622000059
    Figure 0007588622000059
  • Figure 0007588622000060
    Figure 0007588622000060
Patent Text Reader

Abstract

Crystalline solid forms of inhibitors of BET proteins, such as BRD2, BRD3, BRD4, and BRD-t, are provided that are useful in the treatment of diseases such as cancer. The present invention provides a solid form of Compound 1 having the formula: TIFF2022130666000057.tif47153
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application relates to a crystalline solid form of 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one, an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, which is useful in the treatment of diseases such as cancer. This application includes methods for its preparation and intermediates in its preparation. [Background technology]

[0002] Eukaryotic genomes are highly organized within the nucleus of cells. DNA is packaged into chromatin by wrapping around a core of histone proteins to form nucleosomes. These nucleosomes are further compacted by aggregation and folding to form a highly condensed chromatin structure. Although a variety of different condensation states are possible, the cohesiveness of this structure changes during the cell cycle, becoming most compact during cell division. Chromatin structure plays an important role in regulating gene transcription by regulating the access of proteins to DNA. Chromatin structure is controlled by a series of post-translational modifications to histone proteins, primarily within the tails of histones H3 and H4, which extend beyond the core nucleosomal structure. These reversible modifications include acetylation, methylation, phosphorylation, ubiquitination, and sumoylation. These epigenetic marks are written and erased by specific enzymes that modify specific residues within the histone tails, forming the epigenetic code. Other nuclear proteins bind to these marks and exert their output as specified by this information through the regulation of chromatin structure and gene transcription. Increasing evidence links genetic alterations to genes that code for epigenetic modifiers and regulators that lead to abnormalities in histone marks in diseases such as neurodegenerative disorders, metabolic diseases, inflammation, and cancer.

[0003] Histone acetylation is commonly associated with activation of gene transcription because the modification weakens the interaction between DNA and histone proteins, increasing the accessibility of DNA to the transcriptional machinery. Certain proteins bind to acetylated lysine residues in histones to "read" the epigenetic code. Highly conserved protein modules called bromodomains bind to acetylated lysine residues on histones and other proteins. There are more than 60 bromodomain-containing proteins in the human genome.

[0004] The BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins includes four proteins (BRD2, BRD3, BRD4, and BRD-t) that share a conserved structural organization that contains a tandem array of N-terminal bromodomains that can bind to acetylated lysine residues on histones and other proteins. BRD2, BRD3, and BRD4 are expressed ubiquitously, whereas BRDt is restricted to germ cells. BRD proteins play essential, but non-overlapping, roles in regulating gene transcription and controlling cell proliferation. BET proteins associate with large protein complexes including Mediator, PAFc, and super-elongation complexes that control many aspects of gene transcription. BRD2 and BRD4 proteins have been found to remain complexed with chromosomes during mitosis and are required to promote the transcription of key genes, including cyclin D and c-Myc, that initiate the cell cycle (Mochizuki J Biol.Chem.2008 283:9040-9048). BRD4 is essential for recruiting the protein translation elongation factor B complex to the promoters of inducible genes, leading to phosphorylation of RNA polymerase II and stimulating transcription and elongation of proliferative genes (Jang et al. Mol. Cell 2005 19:523-534). In some cases, the kinase activity of BRD4 can directly phosphorylate and activate RNA polymerase II (Devaiah et al. PNAS 2012 109:6927-6932). BRD4-deficient cells show impaired cell cycle progression. BRD2 and BRD3 have been reported to bind to histones around transcriptionally active genes, which may be involved in promoting transcription elongation (Leroy et al, Mol. Cell. 2008 30:51-60).In addition to acetylated histones, BET proteins have been shown to selectively bind acetylated transcription factors, including NF-kB and the RelA subunit of GATA1, thereby directly modulating the transcriptional activity of these proteins and controlling the expression of genes involved in inflammation and hematopoietic differentiation (Huang et al, Mol. Cell. Biol. 2009 29:1375-1387; Lamonica Proc. Nat. Acad. Sci. 2011 108:E159-168).

[0005] Recurrent translocations involving NUT (nuclear protein of the testis) and BRD3 or BRD4 to form a novel fusion oncogene, BRD-NUT, are found in highly malignant forms of epithelial neoplasia (French et al, Cancer Research 2003 63:304-307; French et al, Journal of Clinical Oncology 2004 22:4135-4139). Selective ablation of this oncogene restores normal cell differentiation and reverses the tumorigenic phenotype (Filippakopoulos et al, Nature 2010 468:1068-1073). Genetic knockdown of BRD2, BRD3, and BRD4 has been shown to reduce proliferation and survival of a wide range of hematological and solid tumor cells (Zuber et al, Nature 2011 478:524-528; Delmore et al, Cell 2011 146:904-917). Apart from their role in cancer, BET proteins regulate the inflammatory response to bacterial challenge, and showed a significant reduction in inflammatory cytokine levels and protection from obesity-induced diabetes in BRD2 hypomorphic mouse models (Wang et al Biochem J. 2009 425:71-83; Belkina et al. J. Immunol 2013). In addition, some viruses use these BET proteins to bind their viral genome to host cell chromatin as part of the viral replication process and use BET proteins to promote viral gene transcription and repression (You et al, Cell 2004 117:349-60; Zhu et al, Cell Reports 2012 2:807-816).

[0006] Inhibitors of BET proteins are currently under development. Exemplary BET protein inhibitors are described, for example, in US Patent Application Publication Nos. 2014 / 0275030; 2015 / 0011540; 2015 / 0148375; 2015 / 0148342; 2015 / 0148372; 2015 / 0175604; and 2016 / 007572. Specifically, the BET inhibitor compound 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one is described in US2015 / 0307493. For drug development, it is usually advantageous to use a form of the drug that has desirable properties with respect to its preparation, purification, reproducibility, stability, bioavailability, and other characteristics. Thus, the solid crystalline forms of the compounds provided herein help meet the current demand for the development of BET inhibitors for the treatment of diseases. Summary of the Invention

[0007] In particular, the present application provides a crystalline solid form of a BET protein inhibitor, which is 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one.

[0008] The present application also provides a pharmaceutical composition comprising 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one in crystalline solid form and at least one pharma- ceutically acceptable carrier.

[0009] The application also provides methods of using a crystalline solid form of 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one for the treatment of diseases and disorders associated with activity of BET proteins.

[0010] Further, the present application provides methods for preparing 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one and its crystalline solid forms.

[0011] Furthermore, the present application provides intermediate compounds and methods for preparing the same that are useful in the synthesis of 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one.

[0012] The details of one or more embodiments are set forth in the description below. Other features, objects, and advantages will become apparent from the description and the claims. [Brief description of the drawings]

[0013] [Figure 1] 1 is an X-ray powder diffraction (XRPD) pattern of Form I of Compound 1. [Diagram 2] 1 is a differential scanning calorimetry (DSC) thermogram of Form I of Compound 1. [Diagram 3] 1 is a thermogravimetric analysis (TGA) thermogram of Form I of Compound 1. [Figure 4] 1 is an XRPD pattern of Form II of Compound 1. [Diagram 5] 1 is a DSC thermogram of Form II of Compound 1. [Figure 6] 1 is a TGA thermogram of Compound 1, Form II. [Figure 7] 1 is an XRPD pattern of Form Ia of Compound 1. [Figure 8] 1 is an XRPD pattern of Form III of Compound 1. [Figure 9] 1 is an XRPD pattern of Form IV of Compound 1. [Figure 10] 1 is an XRPD pattern of Form V of Compound 1. [Figure 11] 1 is an XRPD pattern of Form Va of Compound 1. [Figure 12] 1 is an XRPD pattern of Form VI of Compound 1. [Figure 13] 1 is an XRPD pattern of Form VII of Compound 1. [Figure 14] 1 is an XRPD pattern of Form VIII of Compound 1. [Figure 15] 1 is an XRPD pattern of Form IX of Compound 1. [Figure 16] 1 is an XRPD pattern of Form X of Compound 1. [Figure 17] 1 is an XRPD pattern of Form XI of Compound 1. [Figure 18] 1 is an XRPD pattern of Form XII of Compound 1. [Figure 19] 1 is an XRPD pattern of Form XIII of Compound 1. [Figure 20] 1 is an XRPD pattern of Form XIV of Compound 1. [Figure 21] 1 is an XRPD pattern of Form XV of Compound 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Crystalline forms and their preparation methods In particular, the present application provides a crystalline solid form of a BET protein inhibitor, which is 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (see below), referred to herein as "Compound 1." [ka]

[0015] Typically, different crystalline forms of the same substance have different bulk properties, e.g., with respect to hygroscopicity, solubility, stability, etc. Forms with higher melting points often have better thermodynamic stability and are advantageous in extending the shelf life of drug formulations containing the solid form. Forms with lower melting points often have poorer thermodynamic stability but are advantageous in increasing water solubility, leading to improved bioavailability of the drug. For stability against heat and humidity, weakly hygroscopic forms are desirable and are less likely to degrade during long-term storage. Anhydrous forms are often desirable because they allow for consistent manufacture without worrying about weight or composition variations due to changes in solvent or water content. On the other hand, hydrated or solvated forms may be advantageous in that they are less hygroscopic and may exhibit improved humidity stability under storage conditions.

[0016] The crystalline solid forms of the present invention may contain solvents such as water (e.g., hydrated forms) or may be substantially free of water and solvents (e.g., anhydrous forms). In some embodiments, the crystalline solid forms are anhydrous. In further embodiments, the crystalline solid forms are hydrated.

[0017] Compound 1 can be obtained in a solid crystalline form designated Form I, described below and in the Examples. Experimental data indicates that Form I is anhydrous. Form I is characterized by its XRPD pattern and other solid state characteristics. In some embodiments, Form I has a characteristic XRPD peak at about 12.7° in 2-theta. In some embodiments, Form I has one or more characteristic XRPD peaks selected from about 8.7°, about 9.8°, and about 12.7° in 2-theta. In some embodiments, Form I has one or more characteristic XRPD peaks selected from about 8.7°, about 9.8°, about 12.7°, about 21.4°, and about 23.3° in 2-theta.

[0018] In some embodiments, Form I has two or more characteristic XRPD peaks selected from about 8.7°, about 9.8°, about 12.7°, about 21.4°, and about 23.3° in terms of 2-theta.

[0019] In some embodiments, Form I has two or more characteristic XRPD peaks selected from about 8.7°, about 9.8°, about 11.6°, about 12.7°, about 14.7°, about 15.7°, about 20.0°, about 21.4°, about 23.3°, and about 27.1° two-theta.

[0020] In some embodiments, Form I has three or more characteristic XRPD peaks selected from about 8.7°, about 9.8°, about 11.6°, about 12.7°, about 14.7°, about 15.7°, about 20.0°, about 21.4°, about 23.3°, and about 27.1° two-theta.

[0021] In some embodiments, Form I has four or more characteristic XRPD peaks selected from about 8.7°, about 9.8°, about 11.6°, about 12.7°, about 14.7°, about 15.7°, about 20.0°, about 21.4°, about 23.3°, and about 27.1° two-theta.

[0022] In some embodiments, Form I has an XRPD pattern substantially as shown in FIG.

[0023] In some embodiments, Form I has a DSC thermogram characterized by an endothermic peak at a temperature of about 266° C. In some embodiments, Form I has a DSC thermogram substantially as shown in FIG.

[0024] In some embodiments, Form I has a TGA thermogram substantially as shown in FIG.

[0025] Form I can generally be prepared by precipitating Form I from a solution comprising Compound 1 and a solvent. In some embodiments, the solvent comprises methanol, acetone, n-heptane, or a mixture thereof. For example, Form I can be prepared by precipitating Form I from a solution comprising Compound 1 and acetone. Preparation of Form I can include adding Compound 1 to a saturated acetone solution of Compound 1 and stirring the resulting solution at about 25° C. for about 3 days.

[0026] In some embodiments, precipitation of Form I is achieved by (1) decreasing the temperature of a solution of Compound 1 (e.g., a solution of Compound 1 at elevated temperature), (2) concentrating the solution of Compound 1, (3) adding an anti-solvent to a solution of Compound 1, or any combination thereof. In some embodiments, precipitation is achieved by adding an anti-solvent to a solution of Compound 1, where said solution of Compound 1 comprises a protic solvent and an aprotic solvent. In some embodiments, the protic solvent is methanol, the aprotic solvent is acetone, and the anti-solvent is n-heptane. In some embodiments, precipitation of Form I is achieved by adding n-heptane to a solution of Compound 1, where said solution of Compound 1 comprises methanol and acetone.

[0027] In some embodiments, preparing Form I includes: (ia) heating a solution of Compound 1 to a temperature of about 50° C. to about 60° C.; (iia) reducing the volume of a solution of Compound 1 at a temperature of about 50° C. to about 60° C. to produce a low volume solution of Compound 1; (iiia) adding an anti-solvent to a low volume solution of Compound 1 while maintaining the temperature at about 55° C. to about 65° C. to produce a warm solution of Compound 1; and (iva) cooling the hot solution of Compound 1 to a temperature of about 15° C. to about 30° C. to precipitate Form I.

[0028] In some embodiments, preparing Form I includes: (ib) heating a solution of compound 1 (the solution containing methanol and acetone as solvents) to a temperature of about 50° C. to about 60° C.; (iib) reducing the volume of a solution of Compound 1 at a temperature of about 50° C. to about 60° C. to produce a low volume solution of Compound 1; (iiib) adding n-heptane to a low volume solution of Compound 1 while maintaining the temperature at about 55° C. to about 65° C. to produce a warm solution of Compound 1; and (ivb) cooling the hot solution of Compound 1 to a temperature of about 15° C. to about 30° C. to precipitate Form I.

[0029] Compound 1 can also be obtained as a crystalline form designated Form II, described below and in the Examples. Experimental data indicates that Form II is anhydrous. Form II is characterized by its XRPD pattern and other solid-state characteristics. In some embodiments, Form II has a characteristic XRPD peak at about 17.0° 2-theta. In some embodiments, Form II has one or more characteristic XRPD peaks selected from about 17.0° and about 19.3° 2-theta. In some embodiments, Form II has one or more characteristic XRPD peaks selected from about 16.2°, about 17.0°, and about 19.3° 2-theta.

[0030] In some embodiments, Form II has two or more characteristic XRPD peaks selected from about 6.7°, about 9.5°, about 10.5°, about 14.8°, about 16.2°, about 17.0°, about 18.8°, and about 19.3° 2-theta.

[0031] In some embodiments, Form II has three or more characteristic XRPD peaks selected from about 6.7°, about 9.5°, about 10.5°, about 14.8°, about 16.2°, about 17.0°, about 18.8°, and about 19.3° two-theta.

[0032] In some embodiments, Form II has four or more characteristic XRPD peaks selected from about 6.7°, about 9.5°, about 10.5°, about 14.8°, about 16.2°, about 17.0°, about 18.8°, and about 19.3° two-theta.

[0033] In some embodiments, Form II has an XRPD pattern substantially as shown in FIG.

[0034] In some embodiments, Form II has a DSC thermogram characterized by an endothermic peak at a temperature of about 268° C. In some embodiments, Form II has a DSC thermogram substantially as shown in FIG.

[0035] In some embodiments, Form II has a TGA thermogram substantially as shown in FIG.

[0036] Form II can generally be prepared by precipitating Form II from a solution comprising Compound 1 and a solvent. In some embodiments, the solvent comprises tetrahydrofuran (THF), acetone, n-heptane, or a mixture thereof. In some embodiments, the precipitation of Form II is performed by (1) decreasing the temperature of a solution of Compound 1, (2) concentrating a solution of Compound 1, (3) adding an anti-solvent to a solution of Compound 1, or any combination thereof. In some embodiments, the precipitation of Form II is performed by adding an anti-solvent to a solution of Compound 1, where the solution comprises an ethereal solvent and an aprotic solvent. In some embodiments, the ethereal solvent is THF, the aprotic solvent is acetone, and the anti-solvent is n-heptane. In some embodiments, the precipitation of Form II is performed by adding n-heptane to a solution of Compound 1, where the solution of Compound 1 comprises THF and acetone.

[0037] In some embodiments, preparing Form II includes: (ic) heating the solution of Compound 1 to a temperature of about 50° C. to about 60° C.; (iic) reducing the volume of a solution of Compound 1 at a temperature of about 50° C. to about 60° C. to produce a low volume solution of Compound 1; (iiic) adding an anti-solvent to a low volume solution of Compound 1 while maintaining the temperature at about 55° C. to about 65° C. to produce a warm solution of Compound 1; and (ivc) cooling the hot solution of Compound 1 to a temperature of about 15° C. to about 30° C. to precipitate Form II.

[0038] In some embodiments, preparing Form II includes: (id) heating a solution of compound 1 (the solution containing THF and acetone as solvents) to a temperature of about 50° C. to about 60° C.; (iid) reducing the volume of a solution of Compound 1 at a temperature of about 50° C. to about 60° C. to produce a low volume solution of Compound 1; (iiid) adding n-heptane to a low volume solution of Compound 1 while maintaining the temperature at about 55° C. to about 65° C. to produce a warm solution of Compound 1; and (ivd) cooling the hot solution of Compound 1 to a temperature of about 15° C. to about 30° C. to precipitate Form II.

[0039] Compound 1 can also be obtained in solid crystalline forms designated Forms Ia, III, IV, V, Va, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV, as described below and in the Examples. Forms Ia, III, IV, V, Va, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV are characterized by their XRPD patterns and other solid state characteristics.

[0040] In some embodiments, Form Ia has one or more characteristic XRPD peaks selected from about 8.8°, about 10.0°, about 11.7°, about 12.8°, and about 13.5° in 2-theta. In some embodiments, Form Ia has one or more characteristic XRPD peaks selected from about 8.8°, about 10.0°, about 11.7°, about 12.8°, about 13.5°, about 20.0°, about 21.5°, about 22.6°, and about 23.3° in 2-theta. In some embodiments, Form Ia has an XRPD pattern substantially as shown in FIG.

[0041] In some embodiments, Form III has one or more characteristic XRPD peaks selected from about 7.8°, about 12.4°, about 13.1°, about 15.2°, and about 15.5° in 2-theta. In some embodiments, Form III has one or more characteristic XRPD peaks selected from about 7.8°, about 12.4°, about 13.1°, about 15.2°, about 15.5°, about 16.9°, about 17.5°, and about 20.3° in 2-theta. In some embodiments, Form III has an XRPD pattern substantially as shown in FIG.

[0042] In some embodiments, Form IV has one or more characteristic XRPD peaks selected from about 11.2°, about 16.3°, about 18.7°, and about 22.1° 2-theta, hi some embodiments, Form IV has an XRPD pattern substantially as shown in FIG.

[0043] In some embodiments, Form V has one or more characteristic XRPD peaks selected from about 8.2°, about 8.5°, about 14.1°, about 16.3°, and about 17.1° in 2-theta. In some embodiments, Form V has one or more characteristic XRPD peaks selected from about 8.2°, about 8.5°, about 14.1°, about 16.3°, about 17.1°, about 18.9°, about 19.8°, about 21.8°, and about 22.7° in 2-theta. In some embodiments, Form V has an XRPD pattern substantially as shown in FIG.

[0044] In some embodiments, Form Va has one or more characteristic XRPD peaks selected from about 8.7°, about 16.5°, about 17.3°, about 19.9°, and about 21.6° 2-theta. In some embodiments, Form Va has an XRPD pattern substantially as shown in Figure 11. In some embodiments, Form Va has a DSC thermogram characterized by an endothermic peak at a temperature of about 133°C, an endothermic peak at a temperature of about 267°C, or a combination thereof.

[0045] In some embodiments, Form VI has one or more characteristic XRPD peaks selected from about 8.5°, about 9.6°, about 11.4°, and about 12.1° in 2-theta. In some embodiments, Form VI has one or more characteristic XRPD peaks selected from about 8.5°, about 9.6°, about 11.4°, about 12.1°, about 13.5°, about 14.5°, about 15.2°, about 17.1°, about 17.7°, about 18.1°, about 19.2°, and about 20.7° in 2-theta. In some embodiments, Form VI has an XRPD pattern substantially as shown in FIG.

[0046] In some embodiments, Form VII has one or more characteristic XRPD peaks selected from about 9.9°, about 12.2°, about 14.8°, and about 15.7° in 2-theta. In some embodiments, Form VII has one or more characteristic XRPD peaks selected from about 9.9°, about 12.2°, about 14.8°, about 15.7°, about 17.0°, about 17.5°, and about 18.8° in 2-theta. In some embodiments, Form VII has an XRPD pattern substantially as shown in Figure 13. In some embodiments, Form VII has a DSC thermogram characterized by an endothermic peak at a temperature of about 126°C, an endothermic peak at a temperature of about 256°C, an exothermic peak at a temperature of about 260°C, an endothermic peak at a temperature of about 267°C, or a combination thereof.

[0047] In some embodiments, Form VIII has one or more characteristic XRPD peaks selected from about 8.1°, about 8.5°, about 16.2°, and about 17.0° in 2-theta. In some embodiments, Form VIII has one or more characteristic XRPD peaks selected from about 8.1°, about 8.5°, about 16.2°, about 16.6°, about 17.0°, about 17.5°, about 18.0°, about 18.9°, about 19.6°, about 20.1° in 2-theta. In some embodiments, Form VIII has an XRPD pattern substantially as shown in Figure 14. In some embodiments, Form VIII has a DSC thermogram characterized by an endothermic peak at a temperature of about 145°C, an endothermic peak at a temperature of about 265°C, or a combination thereof.

[0048] In some embodiments, Form IX has one or more characteristic XRPD peaks selected from about 8.6°, about 9.1°, about 11.4°, about 13.4°, and about 15.2° in 2-theta. In some embodiments, Form IX has one or more characteristic XRPD peaks selected from about 8.6°, about 9.1°, about 11.4°, about 13.4°, about 15.2°, about 18.2°, about 22.1°, about 22.8°, and about 23.9° in 2-theta. In some embodiments, Form IX has an XRPD pattern substantially as shown in FIG.

[0049] In some embodiments, Form X has one or more characteristic XRPD peaks selected from about 14.9°, about 15.3°, about 15.8°, and about 17.0° in 2-theta. In some embodiments, Form X has one or more characteristic XRPD peaks selected from about 14.9°, about 15.3°, about 15.8°, about 17.0°, about 17.7°, about 18.3°, and about 19.7° in 2-theta. In some embodiments, Form X has an XRPD pattern substantially as shown in Figure 16. In some embodiments, Form X has a DSC thermogram characterized by an endothermic peak at a temperature of about 121°C, an endothermic peak at a temperature of about 267°C, or a combination thereof.

[0050] In some embodiments, Form XI has one or more characteristic XRPD peaks selected from about 8.9°, about 12.8°, about 18.0°, about 21.5°, about 22.6°, and about 23.3° 2-theta, in some embodiments, Form XI has an XRPD pattern substantially as shown in FIG.

[0051] In some embodiments, Form XII has one or more characteristic XRPD peaks selected from about 5.6°, about 11.7°, about 13.8°, and about 14.5° in 2-theta. In some embodiments, Form XII has one or more characteristic XRPD peaks selected from about 5.6°, about 11.7°, about 13.8°, about 14.5°, about 16.9°, about 17.7°, and about 18.7° in 2-theta. In some embodiments, Form XII has one or more characteristic XRPD peaks selected from about 5.6°, about 11.7°, about 13.8°, about 14.5°, about 16.9°, about 17.7°, about 18.7°, about 23.5°, about 24.6°, about 34.3°, about 44.2°, and 44.6° in 2-theta. In some embodiments, Form XII has an XRPD pattern substantially as shown in FIG. In some embodiments, Form XII has a DSC thermogram characterized by an endothermic peak at a temperature of about 264°C.

[0052] In some embodiments, Form XIII has one or more characteristic XRPD peaks selected from about 5.7°, about 8.6°, about 9.8°, and about 11.8° in 2-theta. In some embodiments, Form XIII has one or more characteristic XRPD peaks selected from about 5.7°, about 8.6°, about 9.8°, about 11.8°, about 12.6°, about 13.4°, about 14.1°, about 14.8°, about 16.6°, about 19.1° in 2-theta. In some embodiments, Form XIII has an XRPD pattern substantially as shown in Figure 19. In some embodiments, Form XIII has a DSC thermogram characterized by an endothermic peak at a temperature of 267°C.

[0053] In some embodiments, Form XIV has one or more characteristic XRPD peaks selected from about 4.0°, about 11.2°, about 11.9°, about 14.1°, about 14.8°, and about 15.9° 2-theta. In some embodiments, Form XIV has an XRPD pattern substantially as shown in Figure 20. In some embodiments, Form XIV has a DSC thermogram characterized by an endothermic peak at a temperature of 267°C.

[0054] In some embodiments, Form XV has one or more characteristic XRPD peaks selected from about 7.4°, about 9.6°, about 12.4°, about 13.4°, and about 15.5° in 2-theta. In some embodiments, Form XV has one or more characteristic XRPD peaks selected from about 7.4°, about 9.6°, about 12.4°, about 13.4°, about 15.5°, about 16.9°, about 17.7°, about 19.0°, about 19.5°, about 20.6°, and about 22.5° in 2-theta. In some embodiments, Form XV has an XRPD pattern substantially as shown in Figure 21. In some embodiments, Form XV has a DSC thermogram characterized by an endothermic peak at a temperature of about 85°C, an endothermic peak at a temperature of about 172°C, an exothermic peak at a temperature of about 192°C, an endothermic peak at a temperature of about 268°C, or a combination thereof.

[0055] As used herein, the phrase "solid form" refers to a compound provided herein in either an amorphous state or a crystalline state ("crystalline form" or "crystalline solid" or "crystalline solid form"). Thus, a compound provided herein in a crystalline state may optionally contain a solvent or water in the crystal lattice, for example forming a solvated or hydrated crystal form. As used herein, the term "hydrated" is intended to refer to a crystal form that contains water molecules in the crystal lattice. Examples of "hydrated" crystal forms include hemihydrate, monohydrate, dihydrate, etc. Other hydrate forms, such as channel hydrates, are also included within the meaning of the term.

[0056] The various crystalline forms of the compounds provided herein (e.g., Compound 1) are characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and / or thermogravimetric analysis (TGA). X-ray powder diffraction (XRPD) patterns of reflections (peaks) are usually considered as fingerprints of a particular crystalline form. It is well known that the relative intensities of XRPD peaks can vary widely depending on, among other things, the sample preparation technique, the crystal size distribution, the various filters used, the sample mounting procedure, and the specific instrument used. In some cases, new peaks may be observed or existing peaks may disappear depending on the type or settings of the instrument (e.g., whether or not a Ni filter is used). As used herein, the term "peak" or "characteristic peak" refers to a reflection whose relative height / intensity is at least about 3% of the maximum peak height / intensity. In addition, instrumental differences and other factors may affect the 2-theta values. Thus, peak designations as reported herein may vary above or below by about 0.2° (2 theta), and the terms "substantially" or "about" as used herein in connection with XRPD are intended to refer to such variations.

[0057] Similarly, temperature measurements associated with DSC, TGA, or other thermal experiments can vary by about ±3° C. depending on the equipment, the specific set-up, sample preparation, etc. Thus, crystalline forms reported herein having DSC thermograms "substantially" as shown in any of the figures are understood to take into account such variations.

[0058] The term "crystalline form" is intended to refer to a crystalline material in a particular lattice arrangement. Different crystalline forms of the same material usually have different crystal lattices (e.g., unit cells) and usually have different physical properties due to the differences in the crystal lattices, and sometimes different water or solvent content. The differences in the crystal lattices can be distinguished by solid-state characterization methods such as X-ray powder diffraction (XRPD). Additionally, other characterization methods such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and dynamic vapor sorption (DVS) are useful in distinguishing crystalline forms, as well as in determining stability and solvent / water content.

[0059] Different crystalline forms of a particular substance, such as Compound 1, may include both anhydrous forms of the substance and solvated / hydrated forms of the substance, with each anhydrous and solvated / hydrated form being distinguished from one another by differences in XRPD patterns or other solid state characterization methods that show differences in the crystal lattice. In some cases, a single crystalline form (e.g., as identified by a unique XRPD pattern) may have varying water or solvent content, where the lattice remains substantially unchanged (as does the XRPD pattern) as the composition with respect to water and / or solvent changes.

[0060] In some embodiments, the compounds of the present application (or hydrates and solvates thereof) are prepared in batches, which are referred to as batches, samples, or preparations. A batch, sample, or preparation may contain the compounds provided herein in any of the crystalline or non-crystalline forms described herein, including hydrated and non-hydrated forms, and mixtures thereof.

[0061] The compounds disclosed herein may include all isotopes of the atoms present therein. Isotopes include atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.

[0062] In some embodiments, the compounds provided herein (e.g., Compound 1), or salts thereof, or crystalline forms thereof are substantially isolated. The term "substantially isolated" means that the compounds or salts are at least partially or substantially separated from the environment in which they were formed or detected. Partially isolated may include, for example, compositions enriched in the compounds, salts, or crystalline forms provided herein. Substantially isolated may include compositions containing at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, or at least about 99% by weight of the compounds, salts, or crystalline forms provided herein.

[0063] The phrase "pharmacologically acceptable" as used herein means that such compounds, substances, compositions, and / or dosage forms are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, and are commensurate with a reasonable benefit / risk ratio.

[0064] Method for preparing compound 1 The present application further provides a method for preparing compound 1, which is adaptable to scale-up. The method for preparing compound 1 is described in US2015 / 0307493, which is incorporated herein by reference in its entirety. Compared with the method described in US2015 / 0307493, the method provided herein has the obvious advantage of being adaptable to scale-up. For example, the method provided herein uses less hazardous reagents, and yet produces a high yield and good quality product. Furthermore, the method provided herein can produce compound 7 in situ without isolating compound 7 (see below), improving the efficiency of large-scale production.

[0065] In some embodiments, the method for preparing compound 1 includes the step of preparing compound 8: [ka] with B1, where B1 is a base.

[0066] In some embodiments, B1 is an alkali metal hydroxide base, such as sodium hydroxide. The reaction of compound 8 with B1 can be carried out in a solvent. In some embodiments, the solvent comprises an ether solvent, such as 1,4-dioxane. An ether solvent, such as 1,4-dioxane, can provide compound 1 in high yield and good quality. In some embodiments, the reaction of compound 8 with B1 is carried out at an elevated temperature, for example, at a temperature of about 50° C. to about 85° C. (e.g., about 60° C. to about 80° C. or about 65° C. to about 75° C.). In some embodiments, the temperature is about 70° C. In some embodiments, a molar excess of B1 is provided relative to the amount of compound 8. In some embodiments, about 3 to about 4 equivalents or about 3.5 equivalents of B1 are used, based on 1 equivalent of compound 8.

[0067] In some embodiments, the method further comprises administering to a patient a compound comprising: [ka] Compound 9: [ka] in the presence of P2 and B2 to produce compound 8, where P2 is a transition metal catalyst and B2 is a base.

[0068] In some embodiments, P2 is a transition metal catalyst, such as a palladium catalyst. Examples of palladium catalysts include [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2, e.g., Pd(dppf)Cl2-CH2Cl2), dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]-phosphoranyl})palladium (Pd-132), Pd(PPh3)4, and tetrakis(tri(o-tolyl)phosphine)palladium(0). In some embodiments, P2 is Pd(dppf)Cl2. In some embodiments, B2 is an alkali metal bicarbonate base, such as sodium bicarbonate. In some embodiments, B2 is an alkali metal carbonate base, such as K2CO3. The reaction of compound 7 with compound 9 can be carried out in a solvent. In some embodiments, the solvent comprises a protic solvent, an ether solvent, or a mixture thereof. In some embodiments, the solvent comprises water, 1,4-dioxane, or a mixture thereof. In some embodiments, the reaction of compound 7 with compound 9 is carried out at elevated temperatures, e.g., at a temperature of about 80° C. to about 100° C. (e.g., about 85° C. to about 95° C.). In some embodiments, the temperature is about 90° C. In some embodiments, about 1 equivalent of compound 9 is used based on 1 equivalent of compound 7 or compound 6 (having the structure shown below). In some embodiments, a sufficient catalytic amount of P2 is provided. For example, about 0.01 to about 0.05 equivalents or about 0.03 equivalents of P2 are used based on 1 equivalent of compound 7. In some embodiments, a molar excess of B2 is provided relative to the amount of compound 9. In some embodiments, about 2 to about 3 equivalents or about 2.5 equivalents of B2 are used based on 1 equivalent of compound 9.

[0069] In some embodiments, the method further comprises the step of: [ka] with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) in the presence of P3 and B3 to produce compound 7, where P3 is a transition metal catalyst and B3 is a base.

[0070] In some embodiments, P3 is a transition metal catalyst, such as a palladium catalyst. Examples of palladium catalysts include [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2, e.g., Pd(dppf)Cl2-CH2Cl2), dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]-phosphoranyl})palladium (Pd-132), Pd(PPh3)4, and tetrakis(tri(o-tolyl)phosphine)palladium(0). In some embodiments, P3 is Pd(dppf)Cl2. In some embodiments, B3 is an alkali metal acetate base, such as potassium acetate. The reaction of compound 6 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) can be carried out in a solvent. In some embodiments, the solvent comprises an ether solvent, such as 1,4-dioxane. In some embodiments, the reaction of compound 6 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) is carried out at elevated temperatures, for example, at temperatures of about 70°C to about 90°C (e.g., 75°C to about 85°C). In some embodiments, the temperature is about 80°C. In some embodiments, a molar excess of the reagent 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) is provided relative to the amount of compound 6. In some embodiments, about 2 to about 2.5 equivalents of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) are used, based on 1 equivalent of compound 6. In some embodiments, a molar excess of B3 is provided relative to the amount of compound 6. In some embodiments, about 3 to about 3.5 equivalents of B3 are used, based on 1 equivalent of compound 6. In some embodiments, a sufficient catalytic amount of P3 is provided. In some embodiments, about 0.01 to about 0.05 equivalents or about 0.03 equivalents of P3 are used, based on 1 equivalent of compound 6.

[0071] In some embodiments, after compound 7 is produced, the subsequent reaction to produce compound 8 is carried out in the same reaction vessel without isolating compound 7. When compound 7 is produced and then the reaction to produce compound 8 is carried out in the same reaction vessel (without isolating compound 7), compound 8 can be produced from compounds 7 and 9 without the addition of P2, for example by using P3 (a transition metal catalyst) to produce compound 7 in the same reaction vessel. Alternatively, the coupling reaction to produce compound 8 from compound 6 can be carried out in a two-step process, where compound 7 is isolated and P2 is used in the reaction to produce compound 8 from compound 7.

[0072] Alternatively, compound 8 can be prepared by reacting compound 6 with compound 15: [ka] in the presence of P4 and B4, where P4 is a transition metal catalyst and B4 is a base.

[0073] In some embodiments, P4 is a transition metal catalyst, such as a palladium catalyst. Examples of palladium catalysts include 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1), Pd(dppf)Cl2 (e.g., Pd(dppf)Cl2-CH2Cl2), dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]-phosphoranyl})palladium (Pd-132), Pd(PPh3)4, and tetrakis(tri(o-tolyl)phosphine)palladium(0). In some embodiments, P4 is 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1). In some embodiments, P4 is Pd(dppf)Cl2 (e.g., Pd(dppf)Cl2-CH2Cl2). In some embodiments, B4 is a base, such as cesium fluoride. In another embodiment, B4 is an alkali metal carbonate, such as K2CO3. The reaction between compound 6 and compound 15 can be carried out in a solvent. In some embodiments, the solvent includes a protic solvent, an ether solvent, or a mixture thereof. In some embodiments, the reaction is carried out in a solvent including 1,4-dioxane, water, or a mixture thereof. In some embodiments, the reaction between compound 6 and compound 15 is carried out at an elevated temperature (e.g., above room temperature), such as near the reflux temperature. In some embodiments, about 1 equivalent of compound 15 is used based on 1 equivalent of compound 6. In some embodiments, a molar excess of B4 is provided relative to compound 6. In some embodiments, about 3 to about 4 equivalents or about 3.5 equivalents of B4 are used based on 1 equivalent of compound 6. P4 is typically provided in a sufficient catalytic amount. In some embodiments, about 0.01 to about 0.1 equivalents or about 0.05 equivalents of P4 are used based on 1 equivalent of compound 6.

[0074] In some embodiments, compound 15 can be prepared by a method comprising reacting compound 9 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) in the presence of P8 and B8, where P8 is a transition metal catalyst and B8 is a base.

[0075] In some embodiments, P8 is a transition metal catalyst, such as a palladium catalyst. Examples of palladium catalysts include tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3, 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1), Pd(dppf)Cl2 (e.g., Pd(dppf)Cl2-CH2Cl2), dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]-phosphoranyl})palladium (Pd-132), Pd(PPh3)4, and tetrakis(tri(o-tolyl)phosphino). In some embodiments, P8 is tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3 (e.g., dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (Xphos) can be added as a ligand). In some embodiments, B8 is an alkali metal acetate base, such as potassium acetate. The reaction of compound 9 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi( The reaction of compound 9 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) can be carried out in a solvent. In some embodiments, the solvent comprises an ether solvent, such as 1,4-dioxane. In some embodiments, the reaction of compound 9 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) is carried out at a temperature of about 75°C to about 95°C. In some embodiments, the temperature is about 80°C to about 90°C or about 80°C to about 85°C. In some embodiments, one equivalent of compound 9 is reacted with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane). Based on 1 equivalent of compound 9, about 2 equivalents of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) are used. In some embodiments, a molar excess of B8 is provided relative to compound 9. In some embodiments, based on 1 equivalent of compound 9, about 2 to about 3 equivalents of B8 are used. P8 is typically provided in a sufficient catalytic amount. In some embodiments, based on 1 equivalent of compound 9, about 0.01 to about 0.1 equivalents or about 0.025 equivalents of P8 are used.

[0076] In some embodiments, compound 6 can be prepared according to the procedures of US2015 / 0307493, which is incorporated herein by reference in its entirety.

[0077] In some embodiments, compound 6 is a compound selected from compound 5: [ka] with a methylating agent and B5, where B5 is a base. In some embodiments, the methylating agent is methyl iodide (MeI), dimethyl sulfate, dimethyl carbonate, or tetramethylammonium chloride. In some embodiments, the methylating agent is methyl iodide. In some embodiments, B5 is an alkali metal carbonate base, such as potassium carbonate (K2CO3). In some embodiments, the reaction of compound 5 with the methylating agent can be carried out in a solvent, including, for example, an aprotic solvent, such as N,N-dimethylformamide (DMF). In some embodiments, the reaction of compound 5 with the methylating agent is carried out at a temperature of about 10°C to about 20°C or about 15°C to about 20°C.

[0078] In some embodiments, compound 5 is compound 4: [ka] with 2-bromo-2-methylpropanoyl bromide and B6, where B6 is a base. In some embodiments, B6 is an alkali metal carbonate, such as potassium carbonate (K2CO3). The reaction of compound 4 with 2-bromo-2-methylpropanoyl bromide can be carried out in the presence of a solvent. For example, the solvent includes acetonitrile, water, or a mixture thereof. The reaction of compound 4 with 2-bromo-2-methylpropanoyl bromide can be carried out at an elevated temperature, for example, a temperature of about 60°C to about 90°C. In some embodiments, the temperature is about 75°C.

[0079] In some embodiments, compound 4 is compound 3: [ka] with a reducing agent. In some embodiments, the reducing agent is sodium hydrosulfite or H2 / Raney Ni. The reaction of compound 3 with the reducing agent can be carried out in the presence of a solvent. In some embodiments, the solvent includes a protic solvent (e.g., water and methanol), an ether solvent (tetrahydrofuran), or a mixture thereof. In some embodiments, the reaction of compound 3 with sodium hydrosulfite is carried out in water, tetrahydrofuran, or a mixture thereof. In some embodiments, the reaction of compound 3 with H2 / Raney Ni is carried out in methanol. In some embodiments, the reaction of compound 3 with the reducing agent is carried out at room temperature. In some embodiments, sodium hydrosulfite is used in combination with sodium bicarbonate. The reaction of compound 3 with sodium hydrosulfite and sodium bicarbonate can produce compound 4 under mild process conditions compared to H2 / Raney Ni, which can be dangerous in large-scale production.

[0080] In some embodiments, compound 3 is compound 2: [ka] with N-bromosuccinimide (NBS). The use of NBS allows for high yields and good quality of product in large scale production, e.g., on the kilogram scale. In some embodiments, the reaction is carried out in a solvent that includes an aprotic solvent, such as N,N-dimethylformamide (DMF). In some embodiments, the reaction is carried out at room temperature.

[0081] In some embodiments, compound 2 is compound 1a: [ka] with nitric acid and acetic acid. In some embodiments, the reaction is carried out at a temperature of about 60° C. to about 90° C. or about 75° C. to about 80° C.

[0082] In some embodiments, compound 9 can be prepared according to the procedures of US2015 / 0307493 and WO2013 / 097601, each of which is incorporated by reference in its entirety.

[0083] In some embodiments, compound 9 is compound 14: [ka] with methyl iodide and sodium hydride. In some embodiments, the reaction is carried out in a solvent that includes an aprotic solvent such as N,N-dimethylformamide (DMF).

[0084] In some embodiments, compound 14 is selected from compound 13: [ka] with an acid. In some embodiments, the acid is a strong aqueous acid such as HCl. In some embodiments, the reaction is carried out in a solvent that includes an ethereal solvent such as 1,4-dioxane.

[0085] In some embodiments, compound 13 is selected from compound 12: [ka] with p-toluenesulfonyl chloride (p-TsCl) and sodium hydride (NaH). In some embodiments, the reaction is carried out in a solvent that includes an aprotic solvent such as N,N-dimethylformamide (DMF).

[0086] In some embodiments, compound 12 is selected from the group consisting of compound 11: [ka] with iron (Fe) and acetic acid (HOAc). In some embodiments, the reaction is carried out in a solvent, including an ether solvent, such as tetrahydrofuran (THF). A combination of iron and acetic acid can be used as a reducing agent, and may be a safe alternative to reducing agents such as H2 / Raney Ni, which can be dangerous in large-scale production.

[0087] In some embodiments, compound 11 is selected from the group consisting of compound 10: [ka] with 1,1-diethoxy-N,N-dimethylmethanamine, further with B7, where B7 is a base. In some embodiments, B7 is an alkali metal alkoxide, such as lithium methanolate. In some embodiments, the reaction is carried out in a solvent, including an aprotic solvent, such as N,N-dimethylformamide (DMF).

[0088] In some embodiments, the method for preparing compound 6 includes: (i) reacting compound 1a with nitric acid and acetic acid to produce compound 2; (ii) reacting compound 2 with N-bromosuccinimide (NBS) to form compound 3; (iii) reacting compound 3 with a reducing agent to produce compound 4; (iv) reacting compound 4 with 2-bromo-2-methylpropanoyl bromide and B6 to produce compound 5; and (v) reacting compound 5 with a methylating agent and B5 to form compound 6.

[0089] In some embodiments, the method for preparing compound 9 includes: (i) reacting compound 10 with 1,1-diethoxy-N,N-dimethylmethanamine and then with B7 to produce compound 11; (ii) reacting compound 11 with iron (Fe) and acetic acid (HOAc) to produce compound 12; (iii) reacting compound 12 with p-toluenesulfonyl chloride (p-TsCl) and sodium hydride (NaH) to produce compound 13; (iv) reacting compound 13 with an acid to produce compound 14; and (v) reacting compound 14 with methyl iodide and sodium hydride to produce compound 9.

[0090] In some embodiments, a method for preparing Compound 1 or a salt thereof includes: (i) reacting compound 6 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) in the presence of P3 and B3 to produce compound 7; (ii) reacting compound 7 with compound 9 in the presence of P2 and B2 to produce compound 8; and (iii) reacting compound 8 with B1 to produce compound 1 or a salt thereof.

[0091] In some embodiments, a method for preparing Compound 1 or a salt thereof includes: (i) reacting compound 6 with compound 15 in the presence of P4 and B4 to produce compound 8; and (ii) reacting compound 8 with B1 to produce compound 1 or a salt thereof.

[0092] In some embodiments, a method for preparing Compound 1 or a salt thereof includes: (i) reacting compound 9 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) in the presence of P8 and B8 to produce compound 15; (ii) reacting compound 6 with compound 15 in the presence of P4 and B4 to produce compound 8; and (iii) reacting compound 8 with B1 to produce compound 1 or a salt thereof.

[0093] In some embodiments, the method for preparing Compound 1 includes: (i) reacting compound 1a with nitric acid and acetic acid to produce compound 2; (ii) reacting compound 2 with N-bromosuccinimide (NBS) to form compound 3; (iii) reacting compound 3 with a reducing agent to produce compound 4; (iv) reacting compound 4 with 2-bromo-2-methylpropanoyl bromide and B6 to produce compound 5; (v) reacting compound 5 with a methylating agent and B5 to produce compound 6; (vi) reacting compound 6 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) in the presence of P3 and B3 to produce compound 7; (vii) reacting compound 7 with compound 9 in the presence of P2 and B2 to produce compound 8; and (viii) reacting compound 8 with B1 to produce compound 1.

[0094] In some embodiments, the method for preparing Compound 1 includes: (i) reacting compound 1a with nitric acid and acetic acid to produce compound 2; (ii) reacting compound 2 with N-bromosuccinimide (NBS) to form compound 3; (iii) reacting compound 3 with a reducing agent to produce compound 4; (iv) reacting compound 4 with 2-bromo-2-methylpropanoyl bromide and B6 to produce compound 5; (v) reacting compound 5 with a methylating agent and B5 to produce compound 6; (vi) reacting compound 6 with compound 15 in the presence of P4 and B4 to produce compound 8; and (vii) reacting compound 8 with B1 to produce compound 1.

[0095] In some embodiments, the method for preparing Compound 1 includes: (i) reacting compound 10 with 1,1-diethoxy-N,N-dimethylmethanamine and then with B7 to produce compound 11; (ii) reacting compound 11 with iron (Fe) and acetic acid (HOAc) to produce compound 12; (iii) reacting compound 12 with p-toluenesulfonyl chloride (p-TsCl) and sodium hydride (NaH) to produce compound 13; (iv) reacting compound 13 with an acid to produce compound 14; (v) reacting compound 14 with methyl iodide and sodium hydride to produce compound 9; (vi) reacting compound 7 with compound 9 in the presence of P2 and B2 to produce compound 8; and (vii) reacting compound 8 with B1 to produce compound 1.

[0096] In some embodiments, the method for preparing Compound 1 includes: (i) reacting compound 10 with 1,1-diethoxy-N,N-dimethylmethanamine and then with B7 to produce compound 11; (ii) reacting compound 11 with iron (Fe) and acetic acid (HOAc) to produce compound 12; (iii) reacting compound 12 with p-toluenesulfonyl chloride (p-TsCl) and sodium hydride (NaH) to produce compound 13; (iv) reacting compound 13 with an acid to produce compound 14; (v) reacting compound 14 with methyl iodide and sodium hydride to produce compound 9; (vi) reacting compound 9 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) in the presence of P8 and B8 to produce compound 15; (vii) reacting compound 6 with compound 15 in the presence of P4 and B4 to produce compound 8; and (viii) reacting compound 8 with B1 to produce compound 1.

[0097] In some embodiments, the present invention provides [ka] or a salt thereof.

[0098] In some embodiments, provided herein is a method of reacting compound 6 with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) in the presence of P3 and B3 to produce compound 7.

[0099] It will be understood that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment (provided that the respective embodiments are intended to be combined as if described in a multiple dependent form). Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

[0100] In some embodiments, the hot solution of Compound 1 described herein refers to a solution at a temperature above room temperature. For example, a hot solution of Compound 1 is at a temperature above about room temperature, such as above about 20°C, above about 30°C, above about 40°C, above about 50°C, above about 60°C, above about 70°C, above about 80°C, above about 90°C, or above about 100°C.

[0101] In some embodiments, concentrating a solution as described herein refers to reducing the volume of the solution by evaporating the solvent, heating the solution, applying a vacuum to the solution, or any combination thereof.

[0102] The phrase "alkali metal bicarbonate base", used alone or in combination with other terms, as used herein, refers to a base having the formula M(HCO), where M refers to an alkali metal (e.g., lithium, sodium, or potassium). Examples of alkali metal bicarbonate bases include, but are not limited to, lithium bicarbonate, sodium bicarbonate, and potassium bicarbonate.

[0103] The phrase "alkali metal carbonate base", used alone or in combination with other terms, as used herein refers to a base having the formula M2CO3, where M refers to an alkali metal (e.g., lithium, sodium, or potassium). Examples of alkali metal carbonate bases include, but are not limited to, lithium carbonate, sodium carbonate, and potassium carbonate.

[0104] The phrase "alkali metal hydroxide base", used alone or in combination with other terms, as used herein refers to a base having the formula MOH, where M refers to an alkali metal (e.g., lithium, sodium, or potassium). Examples of alkali metal hydroxide bases include, but are not limited to, lithium hydroxide, sodium hydroxide, and potassium hydroxide.

[0105] The phrase "alkali metal acetate base", used alone or in combination with other terms, as used herein, refers to a base having the formula M(OC(O)CH), where M refers to an alkali metal (e.g., lithium, sodium, or potassium). Examples of alkali metal acetate bases include, but are not limited to, lithium acetate, sodium acetate, and potassium acetate.

[0106] As used herein, the phrase "transition metal catalyst" refers to a metal catalyst (e.g., a palladium catalyst or a nickel catalyst) suitable for catalyzing carbon-carbon coupling reactions. Examples of transition metal catalysts include, but are not limited to, PdCl2(PPh3)2, Pd(PPh3)4, dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]-phosphoranyl})palladium (Pd-132), NiCl2(dppf), and NiCl2(dppp) (where (dppf) refers to 1,1'-bis(diphenylphosphino)ferrocene and (dppp) refers to 1,3-bis(diphenylphosphino)propane).

[0107] Examples of palladium catalysts include, but are not limited to, PdCl2(PPh3)2, Pd(PPh3)4, dichloro(bis{di-tert-butyl[4-(dimethylamino)phenyl]-phosphoranyl})palladium (Pd-132), palladium on carbon, PdCl2, Pd(OAc)2, PdCl2(MeCN)2, tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3, 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1), Pd(dppf)Cl2 (e.g., Pd(dppf)Cl2-CH2Cl2), and tetrakis(tri(o-tolyl)phosphine)palladium(0).

[0108] As used herein, the term "reacting" is used as known in the art and generally refers to combining chemical reagents in a manner that allows for interaction at a molecular level to occur, to effect a chemical or physical transformation. In some embodiments, the reaction involves two reagents, where one or more equivalents of the second reagent are used relative to the first reagent. The reaction steps of the methods described herein can be carried out for times and under conditions suitable for the preparation of a specified product.

[0109] In some embodiments, an antisolvent as described herein refers to a solvent in which compound 1 is less soluble than a solution of another solvent or mixture of solvents. For example, antisolvents can include, but are not limited to, benzene, cyclohexane, pentane, hexane, heptane (e.g., n-heptane), toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-xylene, o-xylene, or p-xylene, octane, indane, nonane, or naphthalene.

[0110] The reactions of the methods described herein can be carried out in a suitable solvent, which can be readily selected by one skilled in the art of organic synthesis. A suitable solvent can be substantially non-reactive with the starting materials (reactants), intermediates, or products at the temperature at which the reaction is carried out, which can range, for example, from the freezing temperature of the solvent to the boiling point of the solvent. A given reaction can be carried out in one solvent or a mixture of solvents. Depending on the particular reaction step, a suitable solvent can be selected for each reaction step. In some embodiments, the reaction can be carried out in the absence of a solvent, such as when at least one of the reagents is a liquid or gas.

[0111] Suitable solvents may include halogenated solvents such as carbon tetrachloride, bromodichloromethane, dibromochloromethane, bromoform, chloroform, bromochloromethane, dibromomethane, butyl chloride, dichloromethane (methylene chloride), tetrachloroethylene, trichloroethylene, 1,1,1-trichloroethane, 1,1,2-trichloroethane, 1,1-dichloroethane, 2-chloropropane, α,α,α-trifluorotoluene, 1,2-dichloroethane, 1,2-dibromoethane, hexafluorobenzene, 1,2,4-trichlorobenzene, 1,2-dichlorobenzene, chlorobenzene, fluorobenzene, mixtures thereof, and the like.

[0112] Suitable ether solvents include dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, tetrahydrofuran (THF), diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether (diglyme), diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, tert-butyl methyl ether, mixtures thereof, and the like.

[0113] By way of example and not limitation, suitable protic solvents may include water, methanol, ethanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1-propanol, 2-propanol, 2-methoxyethanol, 1-butanol, 2-butanol, isobutyl alcohol, tert-butyl alcohol, 2-ethoxyethanol, diethylene glycol, 1-pentanol, 2-pentanol, or 3-pentanol, neopentyl alcohol, tert-pentyl alcohol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol, or glycerol.

[0114] By way of example and not limitation, suitable aprotic solvents may include N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), 1,3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidinone (NMP), formamide, N-methylacetamide, N-methylformamide, acetonitrile, dimethylsulfoxide, propionitrile, ethyl formate, methyl acetate, hexachloroacetone, acetone, ethyl methyl ketone, ethyl acetate, sulfolane, N,N-dimethylpropionamide, tetramethylurea, nitromethane, nitrobenzene, or hexamethylphosphoramide.

[0115] Suitable hydrocarbon solvents include benzene, cyclohexane, pentane, hexane, toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-xylene, o-xylene, or p-xylene, octane, indane, nonane, or naphthalene.

[0116] The reactions of the processes described herein can be carried out in air or under an inert atmosphere. Reactions involving reagents or products that are substantially air-reactive can typically be carried out using techniques for the synthesis of air-labile materials well known to those skilled in the art.

[0117] As used herein, the expressions "ambient temperature" and "room temperature" are understood in the art and generally refer to a temperature near, for example, the reaction temperature, i.e., the temperature of the room in which the reaction is carried out, for example, from about 20° C. to about 30° C.

[0118] How to use Compound 1 or a salt thereof is a BET protein inhibitor and is therefore useful in the treatment of diseases and disorders associated with the activity of BET proteins. Any form of Compound 1, including any of the embodiments described herein, may be used for the uses described herein.

[0119] Compound 1 can inhibit one or more of the BET proteins BRD2, BRD3, BRD4, and BRD-t. In some embodiments, compound 1 selectively inhibits one or more BET proteins over another. By "selective" it is meant that the compound binds to the BET protein with a higher affinity or inhibits the BET protein with a higher potency compared to a reference substance, such as another BET protein. For example, the compound may be selective for BRD2 over BRD3, BRD4, and BRD-t, selective for BRD3 over BRD2, BRD4, and BRD-t, selective for BRD4 over BRD2, BRD3, and BRD-t, and selective for BRD-t over BRD2, BRD3, and BRD-t. In some embodiments, the compound inhibits two or more BET proteins or all of the BET proteins. In general, the selectivity can be at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 500-fold, or at least about 1000-fold.

[0120] Compound 1 is therefore useful for treating BET protein-mediated disorders. The term "BET protein-mediated disorder" or "BET-mediated disorder" refers to any disorder, disease, or condition in which one or more BET proteins, such as BRD2, BRD3, BRD4, and / or BRD-t, or variants thereof, are involved, or where the disease or condition is related to the expression or activity of one or more BET proteins. Compound 1, as an inhibitor of BET proteins, can therefore be used to treat or reduce the severity of diseases and conditions in which BET proteins, such as BRD2, BRD3, BRD4, and / or BRD-t, or variants thereof, are known to be involved.

[0121] Diseases and conditions treatable with Compound 1 include, but are not limited to, cancer and other proliferative disorders, autoimmune diseases, chronic inflammatory diseases, acute inflammatory diseases, sepsis, and viral infections. Diseases can be treated by administering a therapeutically effective amount or dosage of Compound 1 or any of its embodiments, or a pharmaceutical composition thereof, to an individual (e.g., a patient) in need of treatment. The present disclosure also provides a solid form of Compound 1 or any of its embodiments, or a pharmaceutical composition comprising the solid form, for use in treating a BET-mediated disease or disorder. Also provided is the use of a solid form of Compound 1 or any of its embodiments, or a pharmaceutical composition comprising the solid form, in the manufacture of a medicament for treating a BET-mediated disease or disorder.

[0122] Diseases treatable with Compound 1 include cancer, including adrenal gland carcinoma, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrohidroma, acute eosinophilic leukemia, acute erythroleukemia, acute lymphocytic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenoid odontogenic tumor, adenosquamous carcinoma, adipose tissue tumor, adrenal cortical carcinoma, adult T-cell leukemia / lymphoma, aggressive NK cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastoma, anaplastic large cell lymphoma, anaplastic thyroid carcinoma, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytic thyroid carcinoma, and anaplastic thyroid carcinoma. Cell tumor, atypical teratoid rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, brown tumor, Burkitt lymphoma, breast cancer, brain tumor, carcinoma, intraepithelial carcinoma, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, clear cell sarcoma of the kidney, craniopharyngioma, cutaneous T-cell lymphoma, cervical cancer, colorectal cancer, Degos disease, desmoplastic small round cell tumor, diffuse large B-cell lymphoma, dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonal carcinoma, Endocrine tumors, endodermal sinus tumors, enteropathy-type T-cell lymphoma, esophageal cancer, fetal in utero, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglioneuroma, gastrointestinal cancer, germ cell tumors, gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumor of bone, glial cell tumors, glioblastoma multiforme, glioma, gliomatosis cerebri, glucagonoma, gonadoblastoma, granulosa cell tumor, ginandroblastoma, gallbladder cancer, gastric cancer, hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematologic malignancies, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma, intestinal cancer, kidney Pancreatic cancer, laryngeal cancer, lentigo maligna, lethal midline carcinoma, leukemia, Leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant Triton tumor, mantle cell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, medullary breast carcinoma, medullary thyroid carcinoma, medulloblastoma, melanoma, meningioma, Merkel cell carcinoma, mesothelioma, metastatic urothelial carcinoma, mixed Mullerian tumor,Mucinous tumor, multiple myeloma, muscle tissue tumor, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma, nasopharyngeal carcinoma, neurilemmoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, ocular carcinoma, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor, papillary thyroid carcinoma, paraganglioma, pineoblastoma, pineocytoma, pituitary cell tumor, pituitary adenoma, pituitary tumor, plasmacytoma, polyembryomatosis, precursor T-lymphoblastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, primary peritoneal carcinoma, prostate cancer, pancreatic cancer, pharyngeal cancer, peritoneal pseudomyxoma, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyoma, striated muscle The tumor may include, but is not limited to, sarcoma, Richter's transformation, rectal cancer, sarcoma, schwannomatosis, seminoma, Sertoli cell tumor, sex cord stromal tumor, signet ring cell carcinoma, skin cancer, small round blue cell tumor, small cell carcinoma, soft tissue sarcoma, somatostatinoma, sooty warts, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous cell carcinoma, gastric cancer, T-cell lymphoma, testicular cancer, theca cell tumor, thyroid cancer, transitional cell carcinoma, throat cancer, urachal cancer, genitourinary cancer, urothelial carcinoma, uveal melanoma, uterine cancer, verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginal cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, and Wilms' tumor. In some embodiments, the cancer is selected from the group consisting of adenocarcinoma, adult T-cell leukemia / lymphoma, bladder cancer, blastoma, bone cancer, breast cancer, brain cancer, carcinoma, myeloid sarcoma, cervical cancer, colon cancer, esophageal cancer, gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladder cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, intestinal cancer, renal cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, The cancer may be acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), eye cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, gastric cancer, T-cell lymphoma, testicular cancer, thyroid cancer, throat cancer, genitourinary cancer, urothelial carcinoma, uterine cancer, vaginal cancer, or Wilms' tumor.

[0123] In some embodiments, the cancer is a hematological cancer.

[0124] In some embodiments, the cancer is multiple myeloma, acute myeloid leukemia (AML), or diffuse large B-cell lymphoma (DLBCL).

[0125] Diseases treatable with Compound 1 also include MYC-dependent cancers, which are cancers associated with at least one of myc RNA expression or MYC protein expression. Patients eligible for such treatment can be identified by measuring myc RNA expression or MYC protein expression in cancer tissues or cells.

[0126] Diseases treatable with Compound 1 also include non-cancerous proliferative disorders. Examples of treatable proliferative disorders include, but are not limited to, benign soft tissue tumors, bone tumors, brain and spinal tumors, eyelid and orbital tumors, granulomas, lipomas, meningiomas, multiple endocrine neoplasia, nasal polyps, pituitary tumors, prolactinomas, pseudotumor cerebri, seborrheic keratosis, gastric polyps, thyroid nodules, cystic pancreatic tumors, hemangiomas, vocal cord nodules, polyps, and cysts, Castleman's disease, chronic pilonidal disease, dermatofibromas, pilonidal cysts, pyogenic granulomas, and juvenile polyposis syndrome.

[0127] Diseases and conditions treatable with Compound 1 also include chronic autoimmune and inflammatory conditions. Examples of treatable autoimmune and inflammatory conditions include acute, hyperacute, or chronic organ transplant rejection, acute gout, acute inflammatory reactions (such as acute respiratory distress syndrome and ischemia / reperfusion injury), Addison's disease, agammaglobulinemia, allergic rhinitis, allergies, alopecia, Alzheimer's disease, appendicitis, atherosclerosis, asthma, osteoarthritis, juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, and atopic skin. inflammation, autoimmune alopecia, autoimmune hemolytic and thrombocytopenic states, autoimmune hypopituitarism, autoimmune polyendocrine disorders, Behçet's disease, bullous skin diseases, cholecystitis, chronic idiopathic thrombocytopenic purpura, chronic obstructive pulmonary disease (COPD), cirrhosis, degenerative joint disease, depression, dermatitis, dermatomyositis, eczema, enteritis, encephalitis, gastritis, glomerulonephritis, giant cell arteritis, Goodpasture's syndrome, Guillain-Barre syndrome, gingiva inflammation, Graves' disease, Hashimoto's thyroiditis, hepatitis, hypophysitis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), inflammatory pelvic disease, irritable bowel syndrome, Kawasaki disease, LPS-induced endotoxin shock, meningitis, multiple sclerosis, myocarditis, myasthenia gravis, mycosis fungoides, myositis, nephritis, osteomyelitis, pancreatitis, Parkinson's disease, pericarditis, pernicious anemia, pneumonia, primary biliary sclerosing cholangitis, polyarteritis nodosa, psoriasis, retinitis, scleritis, sclera These include scleracierma, scleroderma, sinusitis, Sjogren's disease, sepsis, septic shock, sunburn, systemic lupus erythematosus, tissue graft rejection, thyroiditis, type I diabetes mellitus, Takayasu's arteritis, urethritis, uveitis, vasculitis including giant cell arteritis, vasculitis with organ involvement such as glomerulonephritis, vitiligo, Waldenstrom's macroglobulinemia, and Wegener's granulomatosis.

[0128] Diseases and conditions treatable with Compound 1 also include diseases and conditions involving an inflammatory response to infection with bacteria, viruses, fungi, parasites, or their toxins, such as sepsis, sepsis syndrome, septic shock, endotoxemia, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome, toxic shock syndrome, acute lung injury, ARDS (adult respiratory distress syndrome), acute renal failure, fulminant hepatitis, burns, acute pancreatitis, postoperative syndrome, sarcoidosis, Herxheimer reaction, encephalitis, myelitis, meningitis, malaria, and SIRS associated with viral infections such as influenza, herpes zoster, herpes simplex, and coronavirus.

[0129] Other diseases treatable with compound 1 include viral infections. Examples of treatable viral infections include Epstein-Barr virus, Hepatitis B virus, Hepatitis C virus, herpes virus, human immunodeficiency virus, human papillomavirus, adenovirus, poxvirus, and other episomal DNA viruses. Thus, compound 1 can be used to treat diseases and conditions such as herpes simplex infection and reactivation, herpes simplex, shingles infection and reactivation, chickenpox, shingles, human papillomavirus, cervical tumors, adenovirus infections with acute respiratory disease, and poxvirus infections such as cowpox and smallpox, and African swine fever virus. In some embodiments, compound 1 can be used to treat human papillomavirus infections of the skin or cervical epithelium.

[0130] Diseases and conditions treatable with Compound 1 also include conditions associated with ischemia-reperfusion injury. Examples of such conditions include, but are not limited to, myocardial infarction, cerebrovascular ischemia (stroke), acute coronary syndromes, renal reperfusion injury, organ transplantation, coronary artery bypass grafting, cardiopulmonary bypass surgery, and pulmonary, renal, hepatic, gastrointestinal, or peripheral limb embolism.

[0131] Compound 1 is also useful for the treatment of lipid metabolism disorders through regulation of APO-A1, such as hypercholesterolemia, atherosclerosis, and Alzheimer's disease.

[0132] Compound 1 is also useful in the treatment of fibrotic conditions such as idiopathic pulmonary fibrosis, renal fibrosis, post-operative stenosis, keloid formation, scleroderma, and myocardial fibrosis.

[0133] Compound 1 can also be used to treat ophthalmic indications such as dry eye.

[0134] Compound 1 can also be used to treat cardiac diseases, such as heart failure.

[0135] As used herein, the term "contacting" refers to bringing together the specified components in an in vitro or in vivo system. For example, "contacting" a BET protein with Compound 1 (e.g., Compound 1 in a solid form, such as a crystalline solid form) encompasses administering Compound 1 to an individual or patient, e.g., a human, having a BET protein, as well as introducing, e.g., a solid form of a compound provided herein, into a sample containing a cell preparation or purified preparation containing a BET protein.

[0136] As used herein, the terms "individual" or "patient", which are used synonymously, are used interchangeably and refer to any animal, including a mammal, preferably a mouse, rat, other rodent, rabbit, dog, cat, pig, cow, sheep, horse, or primate, and most preferably a human.

[0137] As used herein, the phrase "therapeutically effective amount" refers to that amount of an active compound or pharmaceutical agent that elicits the biological or medicinal response desired by a researcher, veterinarian, physician, or other clinician in a tissue, system, animal, individual, or human.

[0138] As used herein, the term "treat" or "treatment" refers to inhibiting a disease, e.g., inhibiting the further development of a lesion and / or symptom of a disease, condition, or disorder in an individual experiencing or developing a lesion or symptom of the disease, condition, or disorder, or ameliorating a disease, e.g., ameliorating a disease, condition, or disorder in an individual experiencing or developing a lesion or symptom of the disease, condition, or disorder (i.e., reversing the lesion and / or symptom), e.g., reducing the severity of a disease.

[0139] As used herein, the term "prevent" or "prevention" refers to preventing a disease, e.g., preventing a disease, condition, or disorder in an individual who may be susceptible to the disease, condition, or disorder, but who has not yet experienced or developed the lesions or symptoms of the disease.

[0140] Combination therapy Compound 1 can be used in combination therapy, where Compound 1 is administered in conjunction with other therapies, such as administration of one or more additional therapeutic agents. The additional therapeutic agents are typically those that are commonly used to treat the particular condition being treated. Additional therapeutic agents for the treatment of BET protein-associated diseases, disorders, or conditions can include, for example, chemotherapeutic agents, anti-inflammatory agents, steroids, immunosuppressants, and Bcr-Abl, Flt-3, RAF, FAK, and JAK kinase inhibitors. The one or more additional pharmaceutical agents can be administered to the patient simultaneously or sequentially.

[0141] In some embodiments, compound 1 can be used in combination with therapeutic agents that target epigenetic regulators.Examples of epigenetic regulators include histone lysine methyltransferase, histone arginine methyltransferase, histone demethylase, histone deacetylase, histone acetylase, and DNA methyltransferase.Histone deacetylase inhibitors include, for example, vorinostat.

[0142] Compound 1 can be used in combination with chemotherapeutic agents or other anti-proliferative agents to treat cancer and other proliferative diseases. Compound 1 can also be used in combination with medical therapies such as surgery or radiation therapy, such as gamma radiation, neutron radiation therapy, electron beam radiation therapy, proton therapy, brachytherapy, and unsealed brachytherapy. Examples of suitable chemotherapeutic agents include abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, bleomycin, bortezomib, bortezomib, intravenous busulfan, oral busulfan, calsterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofala. cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alpha 2a, irinotecan, lapatinib nitrile, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, mechlorethamine, megestrol acetate, melphalan, mercaptopril, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin,Sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, and zoledronic acid.

[0143] Compound 1 can be combined with ruxolitinib to treat cancer and other proliferative diseases.

[0144] Compound 1 can be used in combination with one or more immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1, PD-L1, and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR, and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from a KIR inhibitor, a TIGIT inhibitor, a LAIR1 inhibitor, a CD160 inhibitor, a 2B4 inhibitor, and a TGFR beta inhibitor.

[0145] In some embodiments, the inhibitor of an immune checkpoint molecule is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.

[0146] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-1, for example, an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD1 antibody is pembrolizumab.

[0147] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A or MEDI4736.

[0148] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab.

[0149] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of LAG3, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525.

[0150] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of GITR, such as an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or MK-4166.

[0151] In some embodiments, the inhibitor of immune checkpoint molecule is an inhibitor of OX40, such as an anti-OX40 antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562. In some embodiments, the OX40L fusion protein is MEDI6383.

[0152] Compound 1 can be used in combination with one or more drugs for the treatment of diseases such as cancer. In some embodiments, the drug is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of alkylating agents include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).

[0153] To treat autoimmune or inflammatory conditions, Compound 1 can be administered in conjunction with a corticosteroid, such as triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.

[0154] To treat autoimmune or inflammatory conditions, Compound 1 can be administered in conjunction with immunosuppressants such as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol, Alcon), or cyclosporine (Restasis®).

[0155] Compound 1 may be administered in combination with other agents, including Dehydrex™ (Holles Labs), Civamide (Opko), sodium hyaluronate (Vismed, Lantibio / TRB Chemedia), cyclosporine (ST-603, Sirion Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine, doxycycline (ALTY-0501, Alacrity), minocycline, iDestrin™ (NP50301, Nascent), cyclosporine (Davidson, Hartman, Mass. ... Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin, MOLI1901, Lantibio), CF101(2S,3S,4R,5R)-3,4-Dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyl-oxolane-2-carbamyl, Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences), ARG103 (Agentis), RX-10045 (synthetic resolvin analog, Resolvyx), DYN15 (Dyanmis Therapeutics), rivoglitazone (DE011, Daiichi Sanko), TB4 (RegeneRx), OPH-01 (Ophtalmis Monaco), PCS101 (Pericor Science), REV1-31 (Evolutec), lacritin (Senju), rebamipide (Otsuka-Novartis), OT-551 (Othera), PAI-2 (University of Pennsylvania and Temple University) It may be administered in conjunction with one or more additional agents selected from: rituximab, diquafosol tetrasodium (INS365, Inspire), KLS-0611 (Kissei Pharmaceuticals), dehydroepiandrosterone, anakinra, efalizumab, mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267 (TorreyPines Therapeutics), or thalidomide.

[0156] In some embodiments, compound 1 can be administered in combination with one or more agents selected from antibiotics, antivirals, antifungals, anesthetics, anti-inflammatory agents including steroidal and nonsteroidal anti-inflammatory agents, and anti-allergy agents. Examples of suitable agents include aminoglycosides such as amikacin, gentamicin, tobramycin, streptomycin, netilmicin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxins; chloramphenicol; neomycin; paramomycin; colistimethate; bacitracin; vancomycin; cyclosporine ... coumadin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; amphotericins; fluconazole; flucytosine; natamycin; miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen; ketorolac; suprofen; cromolyn; lodoxamide; levocabastine; naphazoline; antazoline; pheniramine; or azalide antibiotics.

[0157] Other examples of one or more agents that may be used in combination with the provided compounds include drugs to treat Alzheimer's disease, such as donepezil and rivastigmine; drugs to treat Parkinson's disease, such as L-DOPA / carbidopa, entacapone, ropinirole, pramipexole, bromocriptine, pergolide, trihexyphenidyl, and amantadine; drugs to treat multiple sclerosis (MS), such as beta interferons (e.g., Avonex® and Rebif®), glatiramer acetate, and mitoxantrone; drugs to treat asthma, such as albuterol and montelukast; drugs to treat schizophrenia, such as Zyprexa, Risperdal, Seroquel, and haloperidol; corticosteroids, such as dexamethasone or prednisone, TNF blockers, IL-1 anti-inflammatory agents such as RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulators including immunosuppressants such as cyclosporine, tacrolimus, rapamycin, mycophenolate mofetil, interferon, corticosteroids, cyclophosphamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anticonvulsants, ion channel blockers, riluzole, or anti-Parkinson's drugs; drugs to treat cardiovascular disease such as beta blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, or statins; drugs to treat liver disease such as corticosteroids, cholestyramine, interferons, and antivirals; drugs to treat blood disorders such as corticosteroids, antileukemias, or growth factors; or drugs to treat immune deficiency disorders such as gamma globulin.

[0158] In some embodiments, compound 1 is administered in combination with a JAK kinase inhibitor (e.g., ruxolitinib, tofacitinib, baricitinib, CYT387, GLPG0634, lestaurtinib, pacritinib, TG101348, or a JAK1 selective inhibitor), a Pim kinase inhibitor (including one or more inhibitors of PIM1, PIM2, and PIM3), a PI3 kinase inhibitor including a PI3K delta selective inhibitor and a broad-spectrum PI3K inhibitor, a MEK inhibitor, a cyclin-dependent kinase inhibitor, a b-RAF inhibitor, an mTOR inhibitor, a proteasome inhibitor (e.g., bortezomib, carfilzomib), an HDAC inhibitor (e.g., panobinostat, vorinostat), a DNA methyltransferase inhibitor, dexamethasone, melphalan, or an immunomodulatory agent (e.g., lenolidomide, pomalidomide).

[0159] Formulation, Dosage Forms, and Administration When used as a pharmaceutical, Compound 1 (e.g., Compound 1 in a solid form, such as a crystalline solid form) can be administered in the form of a pharmaceutical composition. These compositions can be prepared by methods well known in the pharmaceutical art and can be administered by a variety of routes, depending on whether local or systemic treatment is desired and on the area to be treated.

[0160] Administration can be topical (transdermal, epithelial, intraocular, and transmucosal, including intranasal, vaginal, and rectal delivery), pulmonary (e.g., by inhalation or inhalation of powders or aerosols, including nebulizers; intratracheal or intranasal), oral, or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular administration. Parenteral administration can be in the form of a single bolus dose or, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers, aqueous, powder, or oily bases, viscosity agents, and the like may be required or desirable.

[0161] The present application also includes pharmaceutical compositions containing Compound 1 or a pharma- ceutically acceptable salt thereof as an active ingredient in combination with one or more pharma- ceutically acceptable carriers (excipients). In some embodiments, the compositions are suitable for topical administration. In preparing the compositions described herein, the active ingredient is usually mixed with an excipient, diluted with an excipient, or enclosed within such a carrier, for example in the form of a capsule, sachet, paper, or other container. When an excipient functions as a diluent, it can be a solid, semi-solid, or liquid substance that acts as a vehicle, carrier, or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid media), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

[0162] When preparing a formulation, compound 1 can be milled to a suitable particle size before being combined with other ingredients. If compound 1 is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If compound 1 is substantially water-soluble, it can be milled to adjust the particle size to, for example, about 40 mesh, and dispersed almost uniformly in the formulation.

[0163] Compound 1 may be milled using known milling procedures, such as wet milling, to provide a particle size suitable for tablet formulations and other formulation types. Micronized (nanoparticulate) preparations of Compound 1 may be prepared by methods known in the art (see, for example, International Application No. WO2002 / 000196).

[0164] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose.The formulation can further include lubricants such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preservatives such as methylbenzoate and propylhydroxybenzoate; sweeteners; and flavoring agents.The composition provided herein can be formulated to obtain quick release, sustained release, or delayed release of active ingredient after administration to patient by using procedures known in the art.

[0165] The composition can be formulated in a unit dosage form containing a desired amount of the active ingredient. The term "unit dosage form" refers to a physically discrete unit suitable as a unitary dosage for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to obtain a desired therapeutic effect in the presence of a suitable pharmaceutical excipient.

[0166] The active compounds can be effective over a wide dosage range, but are generally administered in a pharma- ceutical effective amount, although it will be understood that the amount of compound actually administered will usually be determined by the physician depending on the relevant circumstances, including the condition being treated, the selected route of administration, the actual compound being administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[0167] When preparing solid compositions such as tablets, the main active ingredient is mixed with pharmaceutical excipients to form a solid preformulation composition containing a homogeneous mixture of the compounds provided herein.When such a preformulation composition is called homogeneous, the active ingredient is generally evenly distributed throughout the composition so that the composition can be easily subdivided into unit dosage forms of equal efficacy, such as tablets, pills, and capsules.This solid preformulation is further subdivided into unit dosage forms of the above types.

[0168] The tablets or pills described herein can be coated or otherwise compounded to provide a dosage form that provides the advantage of sustained action. For example, the tablets or pills can be in the form of an envelope that includes an inner dosage component and an outer dosage component, the outer dosage component covering the inner dosage component. The two components are separated by an enteric layer that is resistant to disintegration in the stomach, allowing the inner component to pass intact to the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, including a number of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.

[0169] Liquid forms into which Compound 1 and compositions described herein may be incorporated when administered orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions, and flavored emulsions with edible oils (such as cottonseed oil, sesame oil, coconut oil, or peanut oil), as well as elixirs and similar pharmaceutical vehicles.

[0170] Compositions for inhalation or inhalation include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents, or mixtures thereof, as well as powders. Liquid or solid compositions may contain suitable pharma- ceutically acceptable excipients as described above. In some embodiments, the compositions are administered by oral or nasal respiratory routes to exert a local or systemic effect. The compositions may be nebulized using an inert gas. The nebulized solution may be inhaled directly from the nebulizing device, or the nebulizing device may be attached to a face mask, tent, or intermittent positive pressure breathing device. Solution, suspension, or powder compositions may be administered orally or nasally from a device that delivers the formulation in an appropriate manner.

[0171] Topical formulations may contain one or more conventional carriers. In some embodiments, ointments may contain water and one or more hydrophobic carriers, such as selected from liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white petrolatum, etc. The carrier composition of creams may be a water-based component in combination with glycerol and one or more other ingredients, such as glycerol monostearate, PEG-glycerol monostearate, and cetylstearyl alcohol. Gels may be formulated using isopropyl alcohol and water, appropriately combined with other ingredients, such as glycerol, hydroxyethylcellulose, etc. Topical formulations may be suitably packaged, for example in 100 g tubes, and may optionally be accompanied by instructions for the treatment of a selected indication, such as psoriasis or other skin conditions.

[0172] The amount of compound or composition administered to a patient will vary depending on what is being administered, the purpose of administration, such as prophylaxis or treatment, the condition of the patient, the method of administration, etc. For therapeutic use, the composition can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. The effective amount will be determined by the judgment of the attending clinician depending on factors such as the pathology of the disease being treated and the severity of the disease, the age, weight, and general condition of the patient.

[0173] The compositions administered to a patient may be in the form of pharmaceutical compositions described above. These compositions may be sterilized by conventional sterilization techniques or may be sterile filtered. Aqueous solutions may be packaged for use as is or lyophilized, with the lyophilized preparation being mixed with a sterile aqueous carrier prior to administration. The pH of the compound preparation is generally 3-11, more preferably 5-9, most preferably 7-8. It will be appreciated that the use of certain of the above excipients, carriers, or stabilizers will result in the form of pharmaceutical salts.

[0174] The therapeutic dose of Compound 1 can vary, for example, according to the particular application to be treated, the method of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compounds provided herein in a pharmaceutical composition can vary depending on several factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration. The dosage can depend on variables such as the type and progression of the disease or disorder, the overall health of a particular patient, the relative biological effectiveness of the selected compound, the excipient formulation, and its route of administration. Effective amounts can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

[0175] The compositions provided herein can further comprise one or more additional pharmaceutical agents, such as chemotherapeutic agents, steroids, anti-inflammatory compounds, or immunosuppressants, examples of which are listed above.

[0176] The present invention will be described in more detail by specific examples. The following examples are provided for illustrative purposes and are not intended to limit the present invention in any manner. Those skilled in the art will readily recognize various non-critical parameters that can be changed or modified to obtain essentially the same results. As described below, the compounds of the examples have been found to be inhibitors of one or more BET proteins. EXAMPLES

[0177] Example 1. Synthesis of 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (Compound 1) The synthesis of intermediate compound 5 was carried out according to Scheme 1. [ka]

[0178] Step 1a. 4-(Methylsulfonyl)-2-nitrophenol (Compound 2) Nitric acid (69%, 4.2 mL, 70 mmol, 1.2 equiv) was added to a stirred solution of 4-(methylsulfonyl)-phenol (compound 1a, 10 g, 58.1 mmol) in acetic acid (HOAc, 91 mL) over 1 min at room temperature. Once an exotherm was observed, the reaction was heated to 70 °C. The reaction mixture was stirred at 75-80 °C for 3 h. Nitric acid (69%, 0.3 mL, 5.0 mmol, 0.086 equiv) was added and the mixture was stirred for an additional 1 h. The reaction mixture was cooled to 15 °C and water (230 mL) was added. After stirring for 30 min, the resulting solid was collected by filtration, rinsed with water (2 × 45 mL), and dried under vacuum at 45 °C for 5 h to give the desired crude product, 4-(methylsulfonyl)-2-nitrophenol (compound 2, 11.0 g). Crude compound 2 was then dissolved in tetrahydrofuran (THF, 110 mL) at 55° C., and warm water (45° C., 275 mL) was slowly added. The solution was gradually cooled to room temperature and stirred at room temperature overnight, then further cooled to 9° C. and stirred at 9° C. for 1 h. The solid was collected by filtration and dried in vacuum at 50° C. overnight to give 4-(methylsulfonyl)-2-nitrophenol (compound 2, 10.15 g, theoretical 12.6 g, yield 80.6%) as a yellow powder. Compound 2: C7H8NO4S (M+H) + LCMS calculated for: 218.0, found: 218.1; 1 H NMR (300 MHz, DMSO-d6) δ 12.20 (br s, 1H), 8.34 (d, J = 2.4 Hz, 1H), 8.00 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H), 7.30 (d, J = 8.8 Hz, 1H), 3.22 (s, 3H) ppm.

[0179] Step 2a. 2-Bromo-4-(methylsulfonyl)-6-nitrophenol (Compound 3) To a solution of 4-(methylsulfonyl)-2-nitro-phenol (compound 2, 825 g, 3.8 mol) in DMF (5.9 L) was added N-bromosuccinimide (NBS, 680 g, 3.82 mol, 1.0 equiv.) at 0° C. The cold bath was removed after 10 min and the reaction mixture was stirred at room temperature for 2 h. When the reaction was complete as determined by LCMS, water (5.9 L) was added and the mixture was stirred at room temperature for 1 h. The solid was filtered, washed with water (3×2.5 L) and dried under vacuum at 45° C. overnight to give 2-bromo-4-(methylsulfonyl)-6-nitrophenol (compound 3, 1085 g, theoretical 1131.1 g, 95.9% yield) as a yellow powder, which was used in the next reaction without further purification. Compound 3: C7H6BrNO5S(MH) - LCMS calculated for: 293.9, found: 294.0; 1 H NMR (300 MHz, DMSO-d6) δ 8.33 (d, J = 2.0 Hz, 1H), 8.31 (d, J = 2.0 Hz, 1H), 3.27 (s, 3H) ppm.

[0180] Step 3a. 2-Amino-6-bromo-4-(methylsulfonyl)phenol (Compound 4) To a solution of 2-bromo-4-(methylsulfonyl)-6-nitrophenol (compound 3, 1037 g, 3.5 mol) and sodium hydrosulfite (Na2S2O4, technical grade 85%, 3.15 kg, 15.4 mol, 4.4 equiv.) in a 1:1 mixture of tetrahydrofuran (THF, 10 L) and water (10 L), sodium bicarbonate (NaHCO3, 2.6 kg, 30.95 mol, 8.8 equiv.) was added portionwise over 1 h. The resulting reaction mixture was stirred at room temperature for 2 h. Once the reaction was complete as determined by LCMS, the reaction mixture was extracted with ethyl acetate (EtOAc, 2×10 L). The combined organic layers were concentrated under reduced pressure. The residue was dissolved in ethyl acetate (EtOAc, 13 L) and the insoluble material was removed by filtration. The filtrate was evaporated under reduced pressure to give crude 2-amino-6-bromo-4-(methylsulfonyl)phenol (compound 4, 736.5 g, theoretical 931.4 g, 79% yield) as a beige powder, which was used in the next reaction without further purification. Compound 4: C7H8BrNO3S (M+H) + LCMS calculated for: 265.9, found: 266.1; 1 H NMR (300 MHz, DMSO-d6) δ 7.15 (d, J = 2.4 Hz, 1H), 7.10 (d, J = 2.4 Hz, 1H), 6.8 (br s, 2H), 3.4 (br s, 1H), 3.09 (s, 3H) ppm.

[0181] Step 4a. 8-Bromo-2,2-dimethyl-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (Compound 5) To a solution of 2-amino-6-bromo-4-(methylsulfonyl)phenol (compound 4, 391 g, 1.47 mol) in acetonitrile (8 L) was added a solution of potassium carbonate (K2CO3, 842 g, 6.1 mol, 4.15 equiv.) in water (2.8 L) at room temperature. 2-Bromo-2-methylpropanoyl bromide (466 mL, 864 g, 3.76 mol, 2.56 equiv.) was then added to the reaction mixture over 20 min at room temperature, and the resulting reaction mixture was stirred at room temperature overnight. Once the corresponding ring-opened intermediate had formed as confirmed by LCMS, the reaction mixture was heated to 75° C. for 6 h. The reaction mixture was concentrated under reduced pressure to half its volume. Water (4 L) and 1N aqueous hydrochloric acid (HCl, 2.24 L) were added, and the mixture was stirred for 15 min. The solid was collected by filtration, washed with water (1.2 L), and dried overnight under vacuum at 50° C. to give the desired crude product (compound 5, 404 g). The crude product was then triturated with a 5:1 mixture of heptane and MTBE (1.2 L) for 3 h at room temperature. The solid was collected by filtration, washed with heptane (1 L), and dried under vacuum to give 8-bromo-2,2-dimethyl-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 5, 401 g, theoretical 491.3 g, yield 81.6%, purity 98%) as a yellow to brown powder. Compound 5:C 11 H 12 BrNO4S(M+H) + LCMS calculated for: 334.0, found: 333.9; 1 H NMR (300 MHz, DMSO-d6) δ 11.10 (s, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.38 (d, J = 2.0 Hz, 1H), 3.22 (s, 3H), 1.46 (s, 6H) ppm.

[0182] Step 5a. 8-Bromo-2,2,4-trimethyl-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 6) A 200 L glass reactor was fitted with an overhead stirrer, thermocouple, addition funnel, and nitrogen inlet, and the apparatus was purged with nitrogen. DMF (30.0 L) and 8-bromo-2,2-dimethyl-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 5, 3000 g, 8.98 mol) were charged to the reactor, and the mixture was stirred at ambient temperature until solution was achieved. Potassium carbonate (K2CO3, 1371 g, 9.92 mol, 1.11 equiv.) and methyl iodide (MeI, 1536 g, 0.67 L, 10.83 mol, 1.21 equiv.) were then charged to the reactor, maintaining the internal temperature at approximately 17° C. The resulting reaction mixture was stirred for approximately 4 h until the methylation reaction was complete as determined by HPLC. Potable water (60.0 L) was charged to the reactor while maintaining the internal temperature at about 19° C., and the mixture was stirred at ambient temperature for about 2.5 hours. The solid was collected by filtration, the wet cake was washed with potable water (30.0 L), air-dried for about 15.5 hours, and then vacuum-dried at about 45° C. to give crude 8-bromo-2,2,4-trimethyl-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 6, 2834 g, theoretical 3127 g, 90.6% yield) as an off-white to yellow powder, which was used in the next reaction without further purification. Compound 6: 1 H NMR (400 MHz, DMSO-d6) δ 7.83 (d, J = 1.9 Hz, 1H), 7.59 (d, J = 1.9 Hz, 1H), 3.37 (s, 3H), 3.31 (d, J = 3.4 Hz, 3H), 1.49 (s, 6H) ppm; 13 C NMR (101 MHz, DMSO-d6) δ 167.47 (s), 144.14 (s), 136.03 (s), 131.46 (s), 126.07 (s), 113.71 (s), 111.25 (s), 79.80 (s), 43.98 (s), 29.42 (s), 24.28 (s) ppm.

[0183] The synthesis of intermediate compound 9 was carried out according to Scheme 2. [ka]

[0184] Step 1b. (E)-2-(5-bromo-2-methoxy-3-nitropyridin-4-yl)-N,N-dimethylethenamine (Compound 11) A solution of lithium methanolate (11.5 g, 0.303 mol, 0.147 equiv) in methanol (300 mL) was added to a solution of 5-bromo-2-methoxy-4-methyl-3-nitropyridine (compound 10, 508 g, 2.057 mol) in DMF (5.0 L). The reaction mixture was heated to 90 °C and 1,1-dimethoxy-N,N-dimethylmethanamine (2180 mL, 8.0 equiv) was added over 10 min. The reaction mixture was stirred at 90-95 °C overnight. Once the reaction was complete as determined by LCMS, the reaction mixture was cooled to 5 °C and ice-cold water (12.2 L) was added via the addition funnel. The mixture was stirred in the cooling bath for 1 h and the precipitated solid was collected by filtration. The solid was washed with ice-cold water (2 L), sucked dry for 2 h, then vacuum dried at 40° C. overnight to give crude (E)-2-(5-bromo-2-methoxy-3-nitropyridin-4-yl)-N,N-dimethylethenamine (compound 11, 506 g, theoretical 619.2 g, yield 81.7%) as a red solid, which was used in the next reaction without further purification. Compound 11: 1 H NMR (300 MHz, DMSO-d6) δ 8.22 (s, 1H), 7.03 (d, J = 3.5 Hz, 1H), 4.79 (d, J = 3.5 Hz, 1H), 3.86 (s, 3H), 2.89 (s, 6H) ppm.

[0185] Step 2b. 4-Bromo-7-methoxy-1H-pyrrolo[2,3-c]pyridine (compound 12) Iron powder (Fe, 1085 g, 19.5 mol, 10 equiv.) and acetic acid (HOAc, 4380 mL, 4595 g, 76.5 mol, 39.3 equiv.) were added sequentially to a solution of (E)-2-(5-bromo-2-methoxy-3-nitropyridin-4-yl)-N,N-dimethylethenamine (compound 11, 587 g, 1.95 mol) in tetrahydrofuran (THF, 5.25 L). The reaction mixture was heated to 40° C., resulting in a gentle, steady exotherm to 77° C. in 1 h. After stirring at 75° C. for an additional 2 h, LCMS confirmed the reaction was complete. The reaction mixture was cooled to 50° C., diluted with ethyl acetate (EtOAc, 4 L) and stirred at room temperature overnight. The solids were removed by filtration through Celite, and the Celite was rinsed with ethyl acetate (EtOAc, 6 L). The combined filtrates were concentrated under reduced pressure. The residue was dissolved in ethyl acetate (EtOAc, 16 L) and the solution was washed with a solution of sodium carbonate (Na2CO3, 900 g) in water (12 L) and saturated brine (2 L). The combined aqueous layers were extracted with ethyl acetate (EtOAc, 4 L). The combined organic layers were evaporated under reduced pressure. Heptane (4 L) was added and the solvent was removed under reduced pressure to give crude 4-bromo-7-methoxy-1H-pyrrolo[2,3-c]pyridine (compound 12, 450 g) quantitatively as a dark solid, which was used in the next reaction without further purification. Compound 12: C8H7BrN2O (M+H) + LCMS calculated for: 227.0, found: 227.1; 1 H NMR (300 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.53 (d, J = 3.0 Hz, 1H), 6.40 (d, J = 3.0 Hz, 1H), 3.99 (s, 3H) ppm.

[0186] Step 3b. 4-Bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine (compound 13) Sodium hydride 60% dispersion in mineral oil (NaH, 120 g, 3 mol, 1.5 equiv.) was added in portions over 15 min to a solution of crude 4-bromo-7-methoxy-1H-pyrrolo[2,3-c]pyridine (compound 12, 450 g, 1.95 mol) in DMF (4.5 L). The temperature of the reaction mixture reached 38 °C. The reaction mixture was stirred for 10 min and then cooled to 20 °C. p-Toluenesulfonyl chloride (p-TsCl, 562 g, 2.95 mol, 1.5 equiv.) was added all at once and the mixture was stirred at room temperature for 2 h. When the reaction was complete as determined by LCMS, water (9 L) was added. The solid was collected by filtration, rinsed with water (2.5 L), and then dissolved in ethyl acetate (EtOAc, 5 L). The solution was washed with water (3 L). The aqueous layer was back extracted with ethyl acetate (EtOAc, 3 L). The combined organic layers were concentrated under reduced pressure to give crude 4-bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine (compound 13, 801 g) quantitatively as a dark solid, which was used in the next reaction without further purification. Compound 13:C 15 H 13 BrN2O3S(M+H) + LCMS calculated for: 381.0; Found: 381.0; 1 H NMR (300 MHz, DMSO-d6) δ 8.15 (d, J = 3.8 Hz, 1H), 7.97 (s, 1 H), 7.83 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 8.5 Hz, 2H), 6.78 (d, J = 3.8 Hz, 1H), 3.80 (s, 3H), 2.36 (s, 3H) ppm.

[0187] Step 4b. 4-Bromo-1-tosyl-1H-pyrrolo[2,3-c]pyridin-7-ol (Compound 14) Crude 4-bromo-7-methoxy-1-tosyl-1H-pyrrolo[2,3-c]pyridine (compound 13, 801 g, 1.95 mol) was dissolved in 4M HCl in 1,4-dioxane (5.6 L, 22.4 mol, 11.5 equiv.) and stirred at 40-45 °C for 12 h. The reaction mixture was concentrated under reduced pressure and the residue was suspended in ethyl ether (Et2O, 1.5 L). The solid was filtered, washed successively with ethyl ether (Et2O, 0.5 L) and heptane (1 L), and then dried overnight in vacuum at 40 °C to give crude 4-bromo-1-tosyl-1H-pyrrolo[2,3-c]pyridin-7-ol (compound 14, 648 g, theoretical 716 g, 90.5% yield over three steps) as a yellow powder, which was used in the next reaction without further purification. Compound 14: C 14 H 11 BrN2O3S(M+H) + LCMS calculated for: 367.0, found: 366.9; 1 H NMR (300 MHz, DMSO-d6) δ 11.46 (s, 1H), 8.01 (d, J = 3.5 Hz, 1H), 7.92 (d, J = 8.2 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 7.33 (s, 1 H), 6.57 (d, J = 3.5 Hz, 1H), 2.36 (s, 3H) ppm.

[0188] Step 5b. 4-Bromo-6-methyl-1-tosyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (Compound 9) Sodium hydride 60% dispersion in mineral oil (NaH, 132 g, 3.3 mol, 1.2 eq) was added in portions over 15 min to a solution of 4-bromo-1-tosyl-1H-pyrrolo[2,3-c]pyridin-7-ol (compound 14, 1000 g, 2.72 mol) in DMF (5 L). The temperature of the reaction mixture reached 39° C. After stirring for 30 min, the reaction mixture was cooled to 20° C. Iodomethane (MeI, 205 mL, 467 g, 3.3 mol, 1.2 eq) was added and the reaction mixture was stirred at room temperature for 2.5 h. Once the reaction was complete as determined by LCMS, water (13 L) was added and the reaction mixture was stirred for 30 min. The solid was filtered and washed successively with water (2.5 L) and heptane (4 L). The solid was then dissolved in dichloromethane (DCM, 9 L) and the solution was transferred to a separatory funnel. Residual water (approximately 200 mL) was removed. The dichloromethane solution was treated with a mixture of sodium sulfate (Na2SO4, 200 g), silica gel (SiO2, 170 g), and activated carbon (20 g) for 1 h. The solids were removed by filtration through a pad of Celite (750 g), and the Celite pad was washed with dichloromethane (DCM, 3 L). Toluene (1.2 L) was added to the combined filtrate. The dichloromethane was removed under reduced pressure. The resulting solid in toluene was collected by filtration, washed successively with toluene (1.2 L) and heptane (1.2 L), and dried under vacuum at 40° C. for 2 hours to give crude 4-bromo-6-methyl-1-tosyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (compound 9, 728 g, theoretical 1036.9 g, yield 70.2%, purity 99.3%), which was used in the next reaction without further purification. Compound 9: C 15 H 13 BrN2O3S(M+H) + LCMS calculated for: 381.0, found: 381.0; 1 H NMR (300 MHz, DMSO-d6) δ 8.03 (m, 1H), 7.93 (m, 2H), 7.78 (s, 1H), 7.41 (m, 2H), 6.58 (m, 1H), 3.37 (s, 3H), 2.36 (s, 3H) ppm.

[0189] The synthesis of compound 1 was carried out according to Scheme 3. [ka]

[0190] Steps 1 and 2. 2,2,4-trimethyl-8-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 8) A 100 L glass reactor was fitted with an overhead stirrer, thermocouple, addition funnel, and nitrogen inlet, and a 22 L glass reactor was fitted with an overhead stirrer, condenser, thermocouple, addition funnel, and nitrogen inlet, each of which was purged with nitrogen. 1,4-Dioxane (15.8 L), 8-Bromo-2,2,4-trimethyl-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 6, 1008 g, 2.90 mol, 1.05 equiv.), bis(pinacolato)diboron (1472 g, 5.80 mol, 2.11 equiv.), and potassium acetate (KOAc, 854 g, 8.70 mol, 3.16 equiv.) were charged to the 100 L reactor. Nitrogen was bubbled through the reaction mixture for 22 minutes and Pd(dppf)Cl2-CH2Cl2 (60.08 g, 0.07 moles, 0.03 equiv.) was rinsed into the 100 L reactor with 1,4-dioxane (0.5 L). Nitrogen was bubbled through the reaction mixture again for 22 minutes. The resulting reaction mixture was heated to gentle reflux (about 81° C.) and stirred at reflux for about 19 hours until the first coupling reaction was complete as determined by HPLC. The reaction mixture was then cooled to about 28° C. Separately, a degassed aqueous solution of sodium bicarbonate was prepared by thoroughly mixing sodium bicarbonate (NaHCO3, 578 g, 6.89 moles, 2.50 equiv.) and potable water (8.3 L) until in solution, then bubbling nitrogen through the solution for about 34 minutes. Degassed aqueous sodium bicarbonate and 4-bromo-6-methyl-1-tosyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one (compound 9, 1050 g, 2.75 mol) were sequentially charged to a 100 L reactor at ambient temperature. The resulting reaction mixture in the 100 L reactor was heated to gentle reflux (about 89° C.) and stirred at reflux for about 2.5 hours until the second coupling reaction was complete as determined by HPLC. The reaction mixture was cooled to about 29° C. and then charged with potable water (26.3 L) and ethyl acetate (EtOAc, 39.4 L). The mixture was stirred at ambient temperature for about 19 minutes and then filtered through a bed of Celite (1050 g). The filter cake was washed with ethyl acetate (EtOAc, 4.2 L). The filtrate and washings were returned to the 100 L reactor, the phases were separated, and the organic phase was left in the reactor.Separately, an aqueous solution of sodium bisulfite was prepared by thoroughly mixing sodium bisulfite (17,052 g) with potable water (41.0 L). Approximately one-third of the aqueous solution of sodium bisulfite (15.6 L) was added to the organic solution in the 100 L reactor, and the resulting mixture was heated to about 50° C. and stirred at about 54° C. for about 1 hour. The mixture was cooled to about 39° C., filtered through the same Celite pad as before, and the filter cake was washed with ethyl acetate (4.2 L). The combined filtrate and washes were returned to the 100 L reactor, the phases were separated, and the organic phase was left in the reactor. Approximately one-third of the aqueous solution of sodium bisulfite (15.6 L) was added to the organic solution in the 100 L reactor, and the resulting mixture was heated to about 50° C. and stirred at about 52° C. for about 1 hour. The reaction mixture was cooled to about 40° C., the phases were separated, and the organic phase was left in the reactor. The remainder of the aqueous sodium bisulfite solution (15.6 L) was added to the organic solution in the 100 L reactor, and the resulting mixture was heated to about 50° C. and stirred at about 50° C. for about 1 hour. The mixture was cooled to about 40° C., the phases were separated, and the organic phase was left in the reactor. The organic phase was washed sequentially with potable water (10.5 L) and an aqueous sodium chloride solution prepared separately from 2100 g sodium chloride and 10.5 L potable water. The organic phase was concentrated under reduced pressure at about 42° C. to a target volume of 11 L (10-12 L per kg of compound 9 charged). The residue was transferred to a 22 L reactor. The organic phase was further concentrated under reduced pressure at about 52° C. to a target volume of 5 L (5-6 L per kg of compound 9 charged). The residue was cooled to about 24° C. and stirred at about 19° C. for about 11.5 hours. The solid was collected by filtration, and the filter cake was washed with n-heptane (4.2 L) and air-dried for about 4 hours, followed by further drying under vacuum at about 15-17° C. to give crude 2,2,4-trimethyl-8-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 8, 1232 g, theoretical 1566.5 g, 78.6% yield) as a yellow to brown powder, which was combined with another batch of crude compound 8 produced by the same procedure and further purified as described below.

[0191] A 100 L glass reactor was fitted with an overhead stirrer, condenser, thermocouple, addition funnel, and nitrogen inlet, and the apparatus was purged with nitrogen. Methylene chloride (34 L) and 2,2,4-trimethyl-8-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one crude (compound 8, 3400 g) were charged to the reactor, and the mixture was stirred at about 17° C. until a solution was obtained. To the resulting solution was added Si-thiol (850 g), and the mixture was heated to about 31° C. and stirred at about 31° C. for about 2.5 hours. The mixture was then cooled to about 20° C. and then filtered. The filter cake was washed with methylene chloride (14 L) and the combined filtrate and washings were concentrated under vacuum at about 32° C. to give purified 2,2,4-trimethyl-8-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 8, 3728 g) as a yellow to brown powder, which was used directly in the next reaction with multiple organic solvents without further drying. Compound 8: 1 H NMR (400 MHz, DMSO-d6) δ 7.99 (dd, J = 5.9, 2.3 Hz, 3H), 7.65 (d, J = 2.0 Hz, 1H), 7.59 (d, J = 2.0 Hz, 1H), 7.56 (s, 1H), 7.44 (d, J = 8.2 Hz, 2H), 6.46 (d, J = 3.5 Hz, 1H), 3.48 (s, 3H), 3.42 (s, 3H), 3.30 (s, 3H), 2.39 (s, 3H), 1.38 (s, 6H) ppm; 13C NMR (101 MHz, DMSO-d6) δ 167.50 (s), 152.60 (s), 145.55 (s), 144.64 (s), 136.22 (s), 135.96 (s), 134.83 (s), 131.27 (s), 130.86 (s), 130.07 (s), 128.88 (s), 125.37 (s), 124.56 (s), 121.93 (s), 113.72 (s), 108.32 (s), 106.83 (s), 79.01 (s), 60.21 (s), 44.17 (s), 36.95 (s), 29.46 (s), 24.28 (s), 21.59 (s), 21.22 (s), 14.55 (s) ppm.

[0192] Step 3. 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (Compound 1) A 50 L glass reactor was fitted with an overhead stirrer, distillation apparatus, thermocouple, addition funnel, and nitrogen inlet, and the apparatus was purged with nitrogen. 1,4-Dioxane (10.2 L) and 2,2,4-trimethyl-8-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 8, 3724 g solvent content from previous step, 3400 g dry equivalent, 5.97 moles) were charged to the reactor with stirring, and the reaction mixture was heated to about 62° C. Separately, an aqueous solution of sodium hydroxide was prepared by thoroughly mixing sodium hydroxide (NaOH, 860 g, 21.49 moles, 3.60 equiv.) with drinking water (21.5 L). Aqueous sodium hydroxide was charged to the reactor over about 26 minutes while maintaining the internal temperature below 70° C. The reaction mixture was heated to about 84° C. and stirred at about 84° C. for about 2.5 hours until the deprotection reaction was complete as determined by HPLC. The reaction mixture was vacuum distilled at about 70° C. to a target volume of 17 L (5 L per kg of compound 8 charged). Potable water (13.6 L) was charged and vacuum distillation continued at about 76° C. until an additional 7 L (2 L per kg of compound 8 charged) was collected. The residual mixture was cooled to about 25° C. and stirred at about 18° C. for about 11 hours. The solid was collected by filtration, the filter cake was washed with water (34 L), and dried on the filter for about 1 hour, followed by air drying for about 5 days to give crude 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 1, 1728 g, theoretical 2480 g, yield 69.7%), which was purified according to the procedure described below.

[0193] A 50 L glass reactor was fitted with an overhead stirrer, thermocouple, and nitrogen inlet, and the apparatus was purged with nitrogen. Acetonitrile (17.2 L) and 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one crude (crude compound 1, 1726 g, 4.25 mol) were charged to the reactor with stirring. The resulting mixture was heated to about 72°C and stirred at 70-75°C for about 1.5 hours. The mixture was then cooled to about 25°C and stirred at ambient temperature for about 1 hour. The solids were collected by filtration, and the filter cake was washed with acetonitrile (9 L) before being transferred back to the reactor along with acetonitrile (17 L). The mixture was heated to about 39° C. and stirred at about 39° C. for about 1.5 hours. The mixture was cooled to about 17° C. and stirred at about 17° C. for about 15 hours. The solid was collected by filtration and the filter cake was washed with methylene chloride (9 L). The product was dehydrated on the filter for about 2 hours and then air-dried for about 1 day to provide purified 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 1, 1458 g, theoretical 1726 g, 84.5% yield), which was recrystallized to obtain the desired crystalline form according to the procedure described below.

[0194] Step 4. Recrystallization of 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (Compound 1) A 100 L glass reactor was fitted with an overhead stirrer, thermocouple, addition funnel, and nitrogen inlet, and a 50 L glass reactor was fitted with an overhead stirrer, condenser, thermocouple, addition funnel, and nitrogen inlet, and each apparatus was purged with nitrogen. Methanol (18.9 L), compound 1 (1454 g), and acetone (18.9 L) were sequentially charged to the 100 L reactor with stirring. The resulting mixture was heated to about 57° C. and stirred at about 57° C. for about 1.25 hours until a clear solution was obtained. The mixture was transferred through an in-line filter to a clean 50 L reactor. Methanol (2.9 L) was rinsed through the 100 L reactor and filter and passed through the filter into the 50 L reactor. The mixture in the 50 L reactor was heated to about 52° C. and stirred at about 56° C. for about 7 minutes until a clear solution was obtained. The solution in the reactor was then concentrated under reduced pressure at about 58° C. until a target volume of 38 L remained. Filtered n-heptane (37.7 L) was charged in portions to the reactor while maintaining the internal temperature below 60 °C. Vacuum distillation was continued at about 59 °C until a target volume of 22 L remained. The residual mixture was cooled to about 24 °C and stirred at about 17 °C for about 6.75 h. The solid was collected by filtration, the filter cake was washed with filtered n-heptane (7.3 L), dehydrated on the filter for about 1 h, and then dried under vacuum at 60-65 °C to provide 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (Compound 1, 1404 g, theoretical 1454 g, 96.6%) as a white to off-white crystalline (Form I) powder. Compound 1:mp 266.4℃; 1 H NMR (400 MHz, DMSO-d6) δ 12.13 (s, 1H), 7.67 (d, J = 1.9 Hz, 1H), 7.62 (d, J = 1.9 Hz, 1H), 7.33 (s, 2H), 6.19 (s, 1H), 3.59 (s, 3H), 3.43 (s, 3H), 3.31 (s, 3H), 1.41 (s, 6H) ppm; 13C NMR (101 MHz, DMSO-d6) δ 167.66 (s), 154.57 (s), 144.55 (s), 134.74 (s), 130.96 (s), 130.33 (s), 129.68 (s), 127.40 (s), 126.96 ppm.

[0195] Form II of crystalline Compound 1 drug substance was obtained by recrystallization in a mixture of tetrahydrofuran (THF), acetone, and n-heptane using a similar procedure as above. Both Form I and Form II have very sharp melting endothermic peaks in DSC, with a difference of about 1°C between the peak melting temperatures of the two forms, 266.4°C for Form I and 267.5°C for Form II. However, Form I and Form II are both stable in aqueous suspension, despite their very different XRD patterns. Studies have shown that Form I is the most stable form in MeOH and acetone, whereas Form II is more stable in IPA. In a mixture of methanol, acetone, and n-heptane, Form I and Form II are interconvertible with each other depending on conditions such as solvent ratio, temperature, and time. Form I and Form II of crystalline Compound 1 have the same solubility in organic solvents and water.

[0196] Form I can also be obtained by adding about 30 mg of Compound 1 to about 2 mL of a saturated or cloudy solution of Compound 1 in acetone, followed by stirring at 25±1° C. for 3 days.

[0197] An alternative synthesis of compound 8 was carried out according to Scheme 4. [ka]

[0198] Step 1x. 6-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one (Compound 15) A 500 mL three-neck round bottom flask made up of a T-tube assembly connected to a mineral oil bubbler was fitted with a condenser and nitrogen inlet. A flask was charged with 4-bromo-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one (compound 9, 10.0 g, 26.2 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (13 g, 52 mmol, 2.0 equiv.), dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (Xphos, 1.2 g, 2.6 mmol, 0.1 equiv.), potassium acetate (5.66 g, 57.7 mmol, 2.2 equiv.), and 1,4-dioxane (110 mL). After the mixture was degassed with nitrogen for 5 min, tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3, 600 mg, 0.656 mmol, 0.025 equiv.) was added to the mixture and nitrogen degassing was continued for 1-2 min. The reaction mixture was then heated to 80 °C and stirred at 80-86 °C for 19 h. Once the reaction was complete as confirmed by HPLC, the reaction mixture was cooled to room temperature. 2-Methoxy-2-methylpropane (MTBE, 50 mL) and silica gel (SiO2, 8 g) were added and the mixture was stirred at room temperature for 30 min. The mixture was filtered through a silica gel pad and the silica gel pad was washed with MTBE. The combined filtrates were concentrated under reduced pressure and the residue was purified by flash column (silica gel, gradient 0-80% EtOAc in hexanes) to give 6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one (compound 15, 9.5 g, theoretical 11.22 g, 84.7%) as a brown to red oil that solidified upon standing at room temperature under vacuum. Compound 15:C 21 H 25 BN2O5S(M+H) + , (2M+Na) +LCMS calculated for: m / z 429.3, 879.3; found: 429.1, 879.3.

[0199] Step 2x. 2,2,4-trimethyl-8-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (Compound 8) 8-Bromo-2,2,4-trimethyl-6-(methylsulfonyl)-2H-1,4-benzoxazin-3(4H)-one (compound 6, 22.4 g, 64.5 mmol) and 6-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrolo[2,3-c A solution of pyridin-7(6H)-one (compound 15, 29.0 g, 67.7 mmol, 1.05 equiv.) was treated with cesium fluoride (CsF, 33.9 g, 223 mmol, 3.46 equiv.) and 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1) (2.0 g, 2.8 mmol, 0.043 equiv.) at ambient temperature. The resulting reaction mixture was then degassed three times, each time filling with a steady stream of nitrogen gas. The reaction mixture was then heated to reflux for 2-3 h. Once the coupling reaction was complete as determined by HPLC, the reaction mixture was gradually cooled to 30° C., after which water (300 mL) and 2-methoxy-2-methylpropane (MTBE, 300 mL) were added. The mixture was then stirred at ambient temperature for 15 min, after which the two layers were separated. The aqueous layer was extracted with methoxy-2-methylpropane (MTBE, 100 mL). The combined extracts were treated with a solution of sodium hydrogen bisulfate (40 g) in water (200 mL) and the resulting mixture was stirred at ambient temperature for 2 h. The solid was collected by filtration, washed with water, and dried overnight in a vacuum oven to give the first crop of the desired product 2,2,4-trimethyl-8-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 8, 20.0 g, theoretical 36.74 g, 54.4% yield) as an off-white to yellow powder, which was used directly in the next reaction without further purification.

[0200] The two layers of the filtrate were separated, and the organic layer was dried over MgSO4 and concentrated under reduced pressure. The residue was then purified by column chromatography (SiO2, gradient elution from 40 to 100% EtOAc in hexanes) to give a second crop of the desired compound 2,2,4-trimethyl-8-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (compound 8, 13.8 g, theoretical 36.74 g, 37.5% yield; total 33.8 g, 91.9% yield) as a pink oil, which solidified under vacuum at room temperature and was used directly in the next reaction without further purification.

[0201] The batch of compound 8 produced by this alternative synthetic process was confirmed to be identical to the material produced by the original synthesis described in Scheme 3. This material was then converted to compound 1 following the same procedure as described in Scheme 3.

[0202] Example 2. X-ray powder diffraction (XRPD) study of Form I and Form II Form I and Form II of Compound 1 were characterized by XRPD. XRPD was obtained from a Bruker D2 PHASER X-ray Powder Diffractometer instrument. The general experimental procedure for XRPD was as follows: (1) K β X-rays were irradiated from a copper source at 1.054056 Å using a filter and a LYNXEYE™ detector; (2) the X-ray power was 30 kV, 10 mA; and (3) the sample powder was dispersed on a background-free sample holder. The general measurement conditions for XRPD were as follows: start angle 5°; stop angle 30°; sampling = 0.015°; and scan rate = 2° / min.

[0203] The XRPD pattern of Form I is shown in FIG. [Table 1]

[0204] The XRPD pattern of Form II of Compound 1 is shown in FIG. 4, and the XRPD data is shown in Table 2. [Table 2]

[0205] Example 3. Differential Scanning Calorimetry (DSC) Study of Form I and Form II Form I and Form II of Compound 1 were characterized by DSC. DSC was obtained from a TA Instruments Differential Scanning Calorimeter, Model Q2000 equipped with an autosampler. The DSC instrument conditions were as follows: 25-300°C at 10°C / min; Tzero aluminum sample pan and lid; and nitrogen gas flow rate of 50 mL / min.

[0206] The DSC thermogram of Form I is shown in Figure 2. The DSC thermogram of Form I showed a large endothermic event with an onset temperature of 264.7°C and a peak temperature of 266.4°C, which is believed to be the melting / decomposition of the compound.

[0207] The DSC thermogram of Form II is shown in Figure 5. The DSC thermogram of Form II showed a large endothermic event with an onset temperature of 266.7°C and a peak temperature of 267.5°C, which is believed to be the melting / decomposition of the compound.

[0208] Example 4. Thermogravimetric Analysis (TGA) Study of Forms I and II Form I and Form II of Compound 1 were characterized by TGA. The TGA was obtained from a PerkinElmer thermogravimetric analyzer, model Pyris 1. The general experimental conditions for the TGA were: 25° C. to 350° C. gradient at 10° C. / min; nitrogen purge gas flow rate of 60 mL / min; ceramic crucible sample holder.

[0209] The TGA thermogram of Form I is shown in Figure 3. A weight loss of about 0.4% was observed up to 150°C, which is believed to be associated with loss of moisture or residual solvent. Significant weight loss was observed above 250°C, which is believed to be associated with decomposition of the compound.

[0210] The TGA thermogram of Form II is shown in Figure 6. Significant weight loss is observed above 250°C, which is believed to be associated with decomposition of the compound.

[0211] Example 5. Preparation of Forms Ia, III, IV, V, Va, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV, and Amorphous Compound 1 Forms Ia, III, IV, V, Va, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV of Compound 1, and amorphous forms of Compound 1, were prepared according to the procedures in Table 3 below. These forms were analyzed by XRPD (see Example 6), DSC (see Example 7), and TGA (see Example 8). [Table 3]

[0212] Example 6. XRPD of Forms Ia, III, IV, V, Va, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV, and Amorphous XRPD testing of Example 5 was carried out on various forms. X-ray powder diffraction (XRPD) was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) K β (1) X-rays were irradiated from a copper source at 1.054056 Å using a filter; (2) the X-ray power was 30 KV, 15 mA; and (3) the sample powder was dispersed on a background-free sample holder. The general measurement conditions for XRPD were as follows: start angle 3°; stop angle 45°; sampling = 0.02°; and scan rate = 2° / min.

[0213] Figures 7-21 are XRPD patterns for Forms Ia, III, IV, V, Va, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV, respectively. Tables 4-18 list the peaks for Forms Ia, III, IV, V, Va, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV, respectively. The amorphous solid of Example 6 was analyzed using XRPD and determined to be amorphous. [Table 4] [Table 5] [Table 6] [Table 7] [Table 8] [Table 9] [Table 10] [Table 11] [Table 12] [Table 13-1] [Table 13-2] [Table 14] [Table 15] [Table 16] [Table 17] [Table 18]

[0214] Example 7. DSC and TGA studies of polymorphs DSC studies were performed on Forms Va, VII, VIII, X, XII, XIII, XIV, and XV. DSC was obtained from a TA Instruments Differential Scanning Calorimeter, Model Q200 equipped with an autosampler. The DSC instrument conditions were: 30-300°C at 10°C / min; Tzero aluminum sample pan and lid; and nitrogen gas flow rate of 50 mL / min.

[0215] TGA studies were performed on Forms Va, VII, VIII, X, XIII, and XV. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for the TGA were: 20°C to 600°C at 20°C / min; nitrogen purge, gas flow rate 40mL / min followed by equilibration of purge flow rate; sample purge flow rate 60mL / min; platinum sample pan.

[0216] Table 19 below shows the DSC and TGA results. [Table 19]

[0217] The present application also includes the following aspects. [Aspect 1] The following formula: [ka] wherein said solid form is crystalline. [Aspect 2] The solid form of embodiment 1, which is anhydrous. [Aspect 3] The solid form according to embodiment 1, having Form I. [Aspect 4] The solid form of embodiment 3, having three or more characteristic XRPD peaks selected from about 8.7°, about 9.8°, about 11.6°, about 12.7°, about 14.7°, about 15.7°, about 20.0°, about 21.4°, about 23.3°, and about 27.1° two-theta. [Aspect 5] The solid form according to embodiment 3, having an XRPD pattern substantially as shown in FIG. [Aspect 6] 6. The solid form of any one of aspects 3-5, having a DSC thermogram characterized by an endothermic peak at a temperature of about 266° C. [Aspect 7] 6. The solid form of any one of embodiments 3-5, having a DSC thermogram substantially as shown in FIG. [Aspect 8] 6. The solid form of any one of embodiments 3-5, having a TGA thermogram substantially as shown in FIG. [Aspect 9] The solid form according to embodiment 1, having Form II. [Aspect 10] The solid form of embodiment 9, having three or more characteristic XRPD peaks selected from about 6.7°, about 9.5°, about 10.5°, about 14.8°, about 16.2°, about 17.0°, about 18.8°, and about 19.3° in 2-theta. [Aspect 11] The solid form of embodiment 9, having an XRPD pattern substantially as shown in FIG. [Aspect 12] 12. The solid form of any one of aspects 9-11, having a DSC thermogram characterized by an endothermic peak at a temperature of about 268° C. [Aspect 13] 12. The solid form of any one of embodiments 9-11, having a DSC thermogram substantially as shown in FIG. 5. [Aspect 14] 12. The solid form of any one of embodiments 9-11, having a TGA thermogram substantially as shown in FIG. [Aspect 15] 15. A pharmaceutical composition comprising a solid form according to any one of aspects 1 to 14 and at least one pharma- ceutically acceptable carrier. [Aspect 16] 16. A method for inhibiting a BET protein, the method comprising contacting said BET protein with a solid form according to any one of aspects 1 to 14 or a pharmaceutical composition according to aspect 15. [Aspect 17] A method for treating a disease or condition associated with a BET protein, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a solid form according to any one of aspects 1 to 14 or a pharmaceutical composition according to aspect 15. [Aspect 18] A method for treating a proliferative disease, comprising administering to a patient in need of such treatment a therapeutically effective amount of a solid form according to any one of aspects 1 to 14 or a pharmaceutical composition according to aspect 15. [Aspect 19] 20. The method of embodiment 18, wherein the proliferative disease is cancer. [Aspect 20] 20. The method of embodiment 19, wherein the cancer is a hematological cancer. [Aspect 21] The cancer is adenocarcinoma, bladder cancer, blastoma, bone cancer, breast cancer, brain tumor, carcinoma, myeloid sarcoma, cervical cancer, colon cancer, esophageal cancer, gastrointestinal cancer, glioblastoma multiforme, glioma, gallbladder cancer, gastric cancer, head and neck cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, intestinal cancer, kidney cancer, laryngeal cancer, leukemia, lung cancer, lymphoma, liver cancer, small cell lung cancer, non-small cell lung cancer, mesothelioma, multiple myeloma, AML, DLB 20. The method of embodiment 19, wherein the cancer is CL, eye cancer, optic nerve tumor, oral cancer, ovarian cancer, pituitary tumor, primary central nervous system lymphoma, prostate cancer, pancreatic cancer, pharyngeal cancer, renal cell carcinoma, rectal cancer, sarcoma, skin cancer, spinal tumor, small intestine cancer, gastric cancer, T-cell leukemia, T-cell lymphoma, testicular cancer, thyroid cancer, throat cancer, genitourinary cancer, urothelial carcinoma, uterine cancer, vaginal cancer, or Wilms' tumor. [Aspect 22] The method of embodiment 19, wherein the cancer is multiple myeloma, AML, or DLBCL. [Aspect 23] The method of embodiment 18, wherein the proliferative disease is a non-cancerous proliferative disorder. [Aspect 24] A method for treating an autoimmune or inflammatory disease, comprising administering to a patient in need of such treatment a therapeutically effective amount of a solid form according to any one of aspects 1 to 14 or a pharmaceutical composition according to aspect 15. [Aspect 25] 25. The method of embodiment 24, wherein the autoimmune or inflammatory disease is selected from allergy, allergic rhinitis, arthritis, asthma, chronic obstructive pulmonary disease, degenerative joint disease, dermatitis, organ rejection, eczema, hepatitis, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, psoriasis, sepsis, septic syndrome, septic shock, systemic lupus erythematosus, tissue graft rejection, and type I diabetes. [Aspect 26] A method for treating a viral infection comprising administering to a patient in need of such treatment a therapeutically effective amount of a solid form according to any one of aspects 1 to 14 or a pharmaceutical composition according to aspect 15. [Aspect 27] 27. The method of embodiment 26, wherein the viral infection is an infection by adenovirus, Epstein-Barr virus, Hepatitis B virus, Hepatitis C virus, herpes virus, human immunodeficiency virus, human papilloma virus, or pox virus. [Aspect 28] Compound 1:

change

change

change

change

change

change

change

change

change

change

change

change

change

Claims

1. The following formula: 【Chemistry 1】 wherein the solid form is crystalline and the solid form has the formula: Form Ia having three or more characteristic XRPD peaks selected from 8.8°±0.2°, 10.0°±0.2°, 11.7°±0.2°, 12.8°±0.2°, 13.5°±0.2°, 20.0°±0.2°, 21.5°±0.2°, 22.6°±0.2°, and 23.3°±0.2° in terms of 2-theta; Form III having three or more characteristic XRPD peaks selected from 7.8°±0.2°, 12.4°±0.2°, 13.1°±0.2°, 15.2°±0.2°, 15.5°±0.2°, 16.9°±0.2°, 17.5°±0.2°, and 20.3°±0.2° in terms of two-theta; Form IV having three or more characteristic XRPD peaks selected from 11.2°±0.2°, 16.3°±0.2°, 18.7°±0.2°, and 22.1°±0.2° in terms of 2-theta; Form V having three or more characteristic XRPD peaks selected from 8.2°±0.2°, 8.5°±0.2°, 14.1°±0.2°, 16.3°±0.2°, 17.1°±0.2°, 18.9°±0.2°, 19.8°±0.2°, 21.8°±0.2°, and 22.7°±0.2° in relation to 2-theta; Form Va having three or more characteristic XRPD peaks selected from 8.7°±0.2°, 16.5°±0.2°, 17.3°±0.2°, 19.9°±0.2°, and 21.6°±0.2° in terms of 2-theta; Form VI having three or more characteristic XRPD peaks selected from 8.5°±0.2°, 9.6°±0.2°, 11.4°±0.2°, 12.1°±0.2°, 13.5°±0.2°, 14.5°±0.2°, 15.2°±0.2°, 17.1°±0.2°, 17.7°±0.2°, 18.1°±0.2°, 19.2°±0.2°, and 20.7°±0.2° in terms of two-theta; Form VII having three or more characteristic XRPD peaks selected from 9.9°±0.2°, 12.2°±0.2°, 14.8°±0.2°, 15.7°±0.2°, 17.0°±0.2°, 17.5°±0.2°, and 18.8°±0.2° in terms of two-theta; Form VIII having three or more characteristic XRPD peaks selected from 8.1°±0.2°, 8.5°±0.2°, 16.2°±0.2°, 16.6°±0.2°, 17.0°±0.2°, 17.5°±0.2°, 18.0°±0.2°, 18.9°±0.2°, 19.6°±0.2°, and 20.1°±0.2° in terms of two-theta; Form IX having three or more characteristic XRPD peaks selected from 8.6°±0.2°, 9.1°±0.2°, 11.4°±0.2°, 13.4°±0.2°, 15.2°±0.2°, 18.2°±0.2°, 22.1°±0.2°, 22.8°±0.2°, and 23.9°±0.2° in terms of 2-theta; Form X having three or more characteristic XRPD peaks selected from 14.9°±0.2°, 15.3°±0.2°, 15.8°±0.2°, 17.0°±0.2°, 17.7°±0.2°, 18.3°±0.2°, and 19.7°±0.2° in terms of 2-theta; Form XI having three or more characteristic XRPD peaks selected from 8.9°±0.2°, 12.8°±0.2°, 18.0°±0.2°, 21.5°±0.2°, 22.6°±0.2°, and 23.3°±0.2° in relation to 2-theta; Form XII having three or more characteristic XRPD peaks selected from 5.6°±0.2°, 11.7°±0.2°, 13.8°±0.2°, 14.5°±0.2°, 16.9°±0.2°, 17.7°±0.2°, 18.7°±0.2°, 23.5°±0.2°, 24.6°±0.2°, 34.3°±0.2°, 44.2°±0.2°, and 44.6°±0.2° in terms of two-theta; Form XIII having three or more characteristic XRPD peaks selected from 5.7°±0.2°, 8.6°±0.2°, 9.8°±0.2°, 11.8°±0.2°, 12.6°±0.2°, 13.4°±0.2°, 14.1°±0.2°, 14.8°±0.2°, 16.6°±0.2°, and 19.1°±0.2° in terms of two-theta; Form XIV having three or more characteristic XRPD peaks selected from 4.0°±0.2°, 11.2°±0.2°, 11.9°±0.2°, 14.1°±0.2°, 14.8°±0.2°, and 15.9°±0.2° in terms of 2-theta; and Form XV having three or more characteristic XRPD peaks selected from 7.4°±0.2°, 9.6°±0.2°, 12.4°±0.2°, 13.4°±0.2°, 15.5°±0.2°, 16.9°±0.2°, 17.7°±0.2°, 19.0°±0.2°, 19.5°±0.2°, 20.6°±0.2°, and 22.5°±0.2° in relation to 2-theta. The solid form is selected from:

2. 2. The solid form of claim 1, wherein the solid form has Form Ia having three or more characteristic XRPD peaks selected from 8.8°±0.2°, 10.0°±0.2°, 11.7°±0.2°, 12.8°±0.2°, 13.5°±0.2°, 20.0°±0.2°, 21.5°±0.2°, 22.6°±0.2°, and 23.3°±0.2° in two-theta.

3. 2. The solid form of claim 1, wherein the solid form has Form III having three or more characteristic XRPD peaks selected from 7.8°±0.2°, 12.4°±0.2°, 13.1°±0.2°, 15.2°±0.2°, 15.5°±0.2°, 16.9°±0.2°, 17.5°±0.2°, and 20.3°±0.2° in terms of two-theta.

4. 2. The solid form of claim 1, wherein the solid form has Form IV having three or more characteristic XRPD peaks selected from 11.2°±0.2°, 16.3°±0.2°, 18.7°±0.2°, and 22.1°±0.2° in terms of two-theta.

5. 2. The solid form of claim 1, wherein the solid form has Form V having three or more characteristic XRPD peaks selected from 8.2°±0.2°, 8.5°±0.2°, 14.1°±0.2°, 16.3°±0.2°, 17.1°±0.2°, 18.9°±0.2°, 19.8°±0.2°, 21.8°±0.2°, and 22.7°±0.2° in terms of two-theta.

6. 2. The solid form of claim 1, wherein the solid form has Form Va having three or more characteristic XRPD peaks selected from 8.7°±0.2°, 16.5°±0.2°, 17.3°±0.2°, 19.9°±0.2°, and 21.6°±0.2° in terms of two-theta.

7. 2. The solid form of claim 1, wherein the solid form has Form VI having three or more characteristic XRPD peaks selected from 8.5°±0.2°, 9.6°±0.2°, 11.4°±0.2°, 12.1°±0.2°, 13.5°±0.2°, 14.5°±0.2°, 15.2°±0.2°, 17.1°±0.2°, 17.7°±0.2°, 18.1°±0.2°, 19.2°±0.2°, and 20.7°±0.2° in two-theta.

8. 2. The solid form of claim 1, wherein the solid form has Form VII having three or more characteristic XRPD peaks selected from 9.9°±0.2°, 12.2°±0.2°, 14.8°±0.2°, 15.7°±0.2°, 17.0°±0.2°, 17.5°±0.2°, and 18.8°±0.2° in terms of two-theta.

9. 2. The solid form of claim 1, wherein the solid form has Form VIII having three or more characteristic XRPD peaks selected from 8.1°±0.2°, 8.5°±0.2°, 16.2°±0.2°, 16.6°±0.2°, 17.0°±0.2°, 17.5°±0.2°, 18.0°±0.2°, 18.9°±0.2°, 19.6°±0.2°, and 20.1°±0.2° in terms of two-theta.

10. 2. The solid form of claim 1, wherein the solid form has Form IX having three or more characteristic XRPD peaks selected from 8.6°±0.2°, 9.1°±0.2°, 11.4°±0.2°, 13.4°±0.2°, 15.2°±0.2°, 18.2°±0.2°, 22.1°±0.2°, 22.8°±0.2°, and 23.9°±0.2° in terms of two-theta.

11. 2. The solid form of claim 1, wherein the solid form has Form X having three or more characteristic XRPD peaks selected from 14.9°±0.2°, 15.3°±0.2°, 15.8°±0.2°, 17.0°±0.2°, 17.7°±0.2°, 18.3°±0.2°, and 19.7°±0.2° in terms of two-theta.

12. 2. The solid form of claim 1, wherein the solid form has Form XI having three or more characteristic XRPD peaks selected from 8.9°±0.2°, 12.8°±0.2°, 18.0°±0.2°, 21.5°±0.2°, 22.6°±0.2°, and 23.3°±0.2° in terms of two-theta.

13. 2. The solid form of claim 1, wherein the solid form has Form XII having three or more characteristic XRPD peaks selected from 5.6°±0.2°, 11.7°±0.2°, 13.8°±0.2°, 14.5°±0.2°, 16.9°±0.2°, 17.7°±0.2°, 18.7°±0.2°, 23.5°±0.2°, 24.6°±0.2°, 34.3°±0.2°, 44.2°±0.2°, and 44.6°±0.2° in terms of two-theta.

14. 2. The solid form of claim 1, wherein the solid form has Form XIII having three or more characteristic XRPD peaks selected from 5.7°±0.2°, 8.6°±0.2°, 9.8°±0.2°, 11.8°±0.2°, 12.6°±0.2°, 13.4°±0.2°, 14.1°±0.2°, 14.8°±0.2°, 16.6°±0.2°, and 19.1°±0.2° in two-theta.

15. 2. The solid form of claim 1, wherein the solid form has Form XIV having three or more characteristic XRPD peaks selected from 4.0°±0.2°, 11.2°±0.2°, 11.9°±0.2°, 14.1°±0.2°, 14.8°±0.2°, and 15.9°±0.2° in terms of two-theta.

16. 2. The solid form of claim 1, wherein the solid form has Form XV having three or more characteristic XRPD peaks selected from 7.4°±0.2°, 9.6°±0.2°, 12.4°±0.2°, 13.4°±0.2°, 15.5°±0.2°, 16.9°±0.2°, 17.7°±0.2°, 19.0°±0.2°, 19.5°±0.2°, 20.6°±0.2°, and 22.5°±0.2° in two-theta.

Citation Information

Patent Citations

  • Crystalline bromodomain inhibitors

    WO2014210425A1

  • 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS

    WO2015164480A1